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Abstract 
The Lamina-associated polypeptide two (LAP2) proteins comprising three human isofonns~ 
LAP2a, LAP2~ and LAP2y have been shown to provide a structural framework in the nucleus 
and to facilitate nuclear assembly and disassembly during the cell cycle. Expression profiling 
studies, using microarrays, identified elevated levels of LAP2a in cervical cancer patient 
material compared to normal. Altered expression of LAP2 may thus have significance in the 
development of certain cancers. The aim of this project was thus to independently confirm the 
up-regulation of LAP2a in cancer material and to determine the effect of inhibiting its 
expression on the biology of cancer and transformed cells. LAP2a mRNA and protein 
expression was shown to be elevated in cervical cancer tissue compared to normal cervical 
tissue by Real-time RT-PCR and immunohistochemical analysis respectively. Interestingly, 
LAP2 (both the LAP2a and LAP2~ isoforms) was shown to be overexpressed in cervical cancer 
cell lines compared to a normal primary cervical epithelial cell line. Higher LAP2 expression 
appears to associate with cellular transformation as increased expression was observed in 
transformed human fibroblast cells compared to normal fibroblasts. LAP2 expression was also 
elevated in oesophageal cancer cell lines compared to normal suggesting that the overexpression 
of LAP2 associates with multiple cancer types. In order to determine the role of LAP2 in cancer 
cell biology~ its expression was inhibited using specific siRNA molecules. Inhibition of LAP2 
did not have an effect on adherent cell proliferation; however under anchorage-independent 
growth conditions a significant decrease in cell proliferation and colony formation was observed 
in LAP2 knockdown cells. This was accompanied by a decrease in cyclin D I levels and an 
increase in p16 levels in LAP2 siRNA transfected cells. Our results did not conclusively show 
xii 
that this decrease in proliferation was as a result of an alteration in the cell cycle profile or due to 
an increase in apoptosis. In addition, inhibition of LAP2 expression resulted in a decrease in Rb 
protein expression. It is proposed that LAP2 plays a role in stabilizing the Rb protein, as 
inhibition of LAP2 expression did not affect Rb mRNA levels but substantially reduced the 
protein half-life. In summary, increased LAP2 expression associates with transformed and 
cancer cells and suggests potential for use as a cancer biomarker. Its potential as an anti-cancer 
therapeutic, however requires further investigation. 
xiii 
Chapter 1: Introduction 
1.1 Cervical cancer as a model system 
1.1.1 Epidemiology of cervical cancer 
Cervical cancer is the second most common form of cancer in women worldwide 
(Kamangar et al., 2005), and within the South African population (Mqoqi et al., 2004). 
The incidence rate is approximately two-fold greater in developing countries, such as 
South Africa, compared to more developed countries (Kamangar et al., 2005). As such, 
cervical cancer has a 0.59 mortality to incidence rate (MR:IR) worldwide with a 
staggering 0.79 MR:IR in Africa compared to 0.30 in North America (Kamangar et al., 
2005). The high incidence of the disease in developing countries is highlighted in Fig. 
1.1. 
The age standardized incidence rate (ASR) of cervical cancer in South Africa, in 1999, 
was 38/100 000 (Mqoqi et al., 2004), where there was a considerable difference in the 
incidence rates between different groups within the population. Black South African 
females had an ASR of 34/100 000 of developing cervical cancer, compared to white 
females with an ASR of 121100 000 (Mqoqi et al., 2004). Collectively, South African 
women have a 1 :31 lifetime risk of developing cervical cancer according to the most 
recent 1999 National Cancer Registry report. 
Fig. 1.1 : Agt'-standardil.~d indd~nc~ and morta lil}' an ofialfd " ilh crI"'\'ica l rannr 
"orld"idr pH 100 000 "Olllell . The Southern African region has the second highest 
Incidcnce of the disease globally aoo a corr~'SpooorngJy higb monalny rale. 
(Sankal1lnarayanan and Fl'!iay, 20(6). 
Papanl.;:olaou ( I'ap) smears are routinely lL~L-d to asSl.-'S.S c}1nlogical ahnomulilK>$ from 
cervical swabs. and are Ihe principle screening melhOO used for prevcl11ing onset of thIS 
di:>ea"". Ho"~\"". tb~rc arc insufficient c'>1\';cal screening prograJJl!l III devdoping 
cnuntri es.. and hence l at~ di agnosi~ is lhouglll to t..;, the majnr contri buting factor as to 
why Ihe mona" ty rat ~ IS"" high in less de,·e!opl.-d countries. 
Th!!. hi~ tological base'll Pap test. while proven to be highly cffeclive in reducing the 
;ncid"nce 800 monalil} of the dis~HSC. dctocls morphological cbanges and thus ollcn has 
a hIgh rale of fa lS<' pogi l iv~ and false negal i,'c rL'Sult~ due In inadC(lua te specificity or 
S<:1L~il" ily of Ihe test (Nanda ,'I ul.. 20(0). Liao CI uf. (199·1) have hlghhghled a need for 
the identi fication of diagnostic binmark.:rs to supplement cytologIcal 1Csts 10 help addrc.s 
some or thl.'Sc problems. 
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1.1.2 ~ lol.,.,IIIH r mechani~ ms in\'ol' ~d in cer, ka l canCer d~, dopmcnl 
Between 90 and 100'"1" of cervical cancer C3SCS are caused by infcCIion wilh the human 
papilloma, IrIlS ~HI'V) and 70% of these cases arc as a result o f inf"'lion wilh cllher lhe 
HI'VI8 or HPVl6 types (Boseh ef Cl/., 2(02). The HPV virus Ulf~'(:Is and repl icates within 
Ihe basal epilhel ial cells of Ihe cervix. The infection is most oflen cleared by the host 
resulting in Hrv type specific immunity, if nOI, Ihc infection can persist resulting in 
ImegratlOn of the viral genome LillO the hosL DNA. wblch can ultimately lead to 
~an;i llOgencsis ( f ig. 1.2). The imronun, discovery that linkerl HrV infection 10 Ihe 
development of cervical cancer was made by Harald zur Hau5<.'tl who shared Ihe Nobel 
Prize for I'hYSlologyor Merlicinc in 2008. 
• 
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Fig. 1.1 HI'\' i nf~lioo Mod l ite de\'l·lopm~nl of cer"inl l cancer. ~The Nobel 
Comminec for Physinlogy or Methcme 2008 1 11 lu~1I'lnioo by Annika Rohl). 
) 
At the molecular level it is accepted that cancer develops in multiple stages through the 
alteration of expression, or activity, of multiple protein encoding genes (Farber, 1984). In 
the case of cervical cancer, this is triggered by high levels of viral encoded early 
oncoproteins, E6 and E7, which can bind to, and inactivate, the growth regulatory 
proteins, p53 and retinoblastoma (Rb) respectively (reviewed in Bosch et al., 2002). The 
presence of the HPV virus, which affects the activity of tumour suppressor proteins, and 
hence other cell cycle regulatory genes, as well as mutations in other important cell cycle 
genes, leads to cellular transformation which can ultimately result in the development of 
cervical cancer. However, in line with the multistep-multigene hypothesis, there are 
additional cofactors that are necessary for viral-induced carcinogenesis; including 
environmental factors such as smoking and diet, as well as host-related factors such as 
susceptibility to specific genetic mutations (Tjalma et al., 2005). 
Genetic mutations can thus result in the transformation of normal cells into cancer cells. 
These cancer cells are characterized by a number of properties described by Hanahan and 
Weinberg (2000). These include the ability to replicate indefinitely, the loss of response 
to tumour suppressor proteins, as well as the self-induction of pro-growth signals, which 
allows cancer cells to proliferate in an uncontrolled manner. This is facilitated by the fact 
that cancer cells are able to avoid programmed cell death (apoptosis), can metastasize 
from the primary tumour site to other regions of the body, and can generate their own 
blood supply (Hanahan and Weinberg, 2000). 
4 
These characteristics of individual cancer cells manifest themselves at a histological 
level, where cervical cancer can be observed to progress through several detectable 
stages. Cervical intraepithelial neoplasia stage I (CIN I), or mild dysplasia, is defined by 
the presence of abnormal, enlarged nuclei in cells in the lower epithelial layer, while the 
middle and upper sections still contain 'normal' cells undergoing differentiation. CIN II 
is characterized by the presence of these abnormal cells in the lower and middle sections 
of the epithelium, while CIN III represents a state where there are few undifferentiated 
cells, and irregular cells are present throughout the epithelium, including the upper layer 
(Buckley et al., 1982). The final step in cancer development is the progression to invasive 
squamous cell carcinoma (zur Hausen, 2000). This sequence of pathological changes is 
associated with alterations in gene expression which are essential to the development of 
cancer. 
Two prophylactic vaccines preventing HPV infection, and thus the development of 
cervical cancer, have been developed, and are currently available on the market. The frrst, 
Gardasil®, developed by Merck protects against four HPV types (HPV6, 11, 16, 18) 
(Sharma and Sharma, 2007) while the GlaxoSmithKline developed, Cervarix® vaccine, 
is bivalent against HPV 16 and 18 (Kyrigou and Shafi, 2008). Consequently, neither of 
these vaccines protects against all HPV types and their effectiveness in protecting against 
the disease in the long term is still unknown. They are both expensive, at about $100 per 
course, and are thus not viable solutions for use in developing countries where prevention 
is needed most. In addition, the vaccines are only a preventative measure and have no 
benefit to people who have already contracted the disease. 
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1.1.3 Expression profiling in cervical cancer 
In order for the alterations in gene expression in the cancer state to be studied, expression 
profiling in matched normal and tUmour tissue can be performed. A study in our 
laboratory aimed at identifying gene targets that associate with cervical cancer using 
cDNA micro array analysis, and a cohort of cervical cancer patient tissue samples, has 
quantitatively shown that there are a wide range of genes that are differentially expressed 
in cancer cells compared to normal cells (Table 1) (van der Watt et al., unpublished data). 
Many of the genes identified are known to be involved in important cellular processes 
often disrupted in cancer (such as cell cycle, cell division, signalling, metabolism and cell 
adhesion) and hence may serve as potential markers of the disease and pose as attractive 
therapeutic targets. In this study, the potential of Lamina-associated polypeptide 2 
(LAP2)/thymopoietin (TMPO) as a marker and therapeutic target, will be investigated in 
transformed and cancer cells. LAP2 was selected based on the following criteria: (1) a 
highly significant three-fold change in expression in cancer compared to normal tissue, 
which has been observed in two independent data sets [(van der Watt et al., 2009) and 
(Rosty et al., 2005)]. The observed overexpression of LAP2 in cervical cancer in studies 
performed in our laboratory is in agreement with the findings of a similar study 
conducted by Rosty et al. (2005). They identified a "cervical cancer proliferation cluster" 
of genes (one of which was LAP2) the expression of which correlates with that of HPV 
E61E7 mRNA (Rosty et al., 2005). (2) An additional criterion was based on the important 
6 
role that LAP2 plays in cell dynamics, nuclear structure and regulation of transcriptional 
activity as discussed below. 
Tatk I. Rtpmientative genes difi:rentially expressed in cervical cane« tissue COOlpIII'Cd In normal cavil< 
Gene D\!li4:rIpdGII WtldIIa&e p-Value 
KPNA2 Ka!)qlherin aIpba 2 (RAG cobort I. impatin alpha I) 4 7.8E-09 
0CI'5 Olaperonin containing TCPI, submit 5 (cpsiloo) 4 2.2&06 
M1HFD2 Methylenetelrahydro{ote dch}drogenase 2 3 2.8&04 
RAN RAN, mernIu RAS oncogene liunily 3 2.1&06 
SNRPB Small nuclear nboouc\eqlrolein poI;peptides B and BI 3 5.8&06 
HOOf HepatonJa.derived grO\\1h fiIctor (high-lIlllilility group pnXein I·like) 3 5.5E-05 
}l)P60 heat shock 60kD pnXein I (chaperonin) 3 8.713-05 
SLC25A5 Solute canier fiuni)y 25 (mitochondrial carrier) 3 1.4&04 
PCNA ProImrating cell nuclear antigen 3 8.413-07 
STMNI Slatlunin 1/0DCqlI'0Iein 18 3 7.513-07 
TMPO 1bymupoIedDILAP 3 2.9&04 
TPM3 T~3 3 2.4E-09 
lHBS2 'fhrcmlxx;poodi 2 2 4.7E-05 
ITGBI Jntegrin, beta I 2 4.0&04 
HSP90BI Heat shock pnXein 90kDa beta (0rp94), mernIu I 2 6.513-05 
p-oIOCIldherin alpha 9 2 3.713-07 
Tnmscribed locus 2 4.8&04 
PSMDll Proteasane (pra;ome, macropain) 268 subunit, noo-A'JPase, II 2 2.4E-05 
XPOI F.lq.min I (CRMI Imdog, )IC8SI) 2 4.513-04 
TMSBIO Thymosin, beta 10 2 3.913-07 
KPNBI Ka!)qlherin (impatin) beta I 2 7.SE-05 
Gmcs _1OId IlpIqOl!aIcd in """"",.,..,m-~ "'_ pqJ.OOO5 
Table 1: Genes differentially expressed in cervical cancer tissue compared to normal 
tissue (van der Watt et al., 2009 and unpublished data). 
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1.2 Tbymopoietin/Lamina-associated polypeptide 2 (LAP2) 
1.2.1 Characterisation of ThymopoietinILAP2 
LAP2 was originally identified as a 49 amino acid protein called thymopoietin (Basch 
and Goldstein, 1974). Thymopoietin is in fact, a proteolytic cleavage product of the N-
terminus of the LAP2 protein which was generated during the isolation and 
characterisation of the protein from bovine thymic tissue (Harris et al., 1995) and shown 
to be involved in thymocyte differentiation (Basch and Goldstein, 1974). It was later 
determined that three different isofonns of human thymopoietinlLAP2 exist; namely: a, 
~, and y, which arise from alternative splicing of the mRNA transcript (Harris et al., 
1994). These isofonns were subsequently shown to be expressed in a variety of tissues, 
suggesting that they may have functions other than thymocyte differentiation (Harris et 
al., 1994). 
The human LAP2 isofonns (LAP2a , LAP2~ , LAP2y) are encoded by a single LAP2 
gene and are alternatively spliced from eight exons to produce proteins of differing 
molecular weights; 75 kD, 51 kD and 39 kD for LAP2a , LAP2~ and LAP2y respectively 
(Harris et al., 1994). The three isofonns share a common 187 amino acid N-terminal 
region, of which the first 49 amino acids correspond to the originally identified 
thymopoietin protein. The alpha isofonn contains a unique 506 amino acid C-terminal 
tail, while the beta and gamma isofonns differ only by a 109 amino acid beta specific 
domain (Harris et al., 1994). The alpha isofonn of LAP2 is non-membrane bound and is 
8 
elilClllially nucleoplasmic: localising 10 the imenor of the nucleus, unlike lIS bet. and 
!;IImm. counlcl'-pans wInch cOIltam a tl'1lllSmembrane dom.1n "I(! arc thus anc~ In me 
Inncr nuclear membrane (Dcch,1 "~I aln 1998; ( Fig. 1.3). 
1\1 0\1 
I~" .. .~ 
LAP!a , '. - ' t.. . .... " ., 
,~ .. m 
........ • 
t' IK. 1.3: Schematic r"prrs"Dlation of th" humaD LAP} alpha, brl •• nd gamma 
I~o ronns. Numbcrl ,ndkl1c amiI'M> kid I'OI'lIions. 1M: Inner nuclear ml.'mbrlne, OM: 
OUI~"" nucka. mcrnbr.nc. (AdlJltcd from D«hBt ("I ul .. 2000b). 
rl m., 1996) The disoo~ery of ~~C1l mRNA IranscnplJ from the homologous mouse 
lanuIl.I-as5()Ciated polypeptide 2, IUUestS the ui~lcnce of more thllll the thrcc o riginally 
disoo,ered human fonns tBerier ('/ al,. 1996) While the LAP2f\I!l(lform il COllsc ..... cd 
200l). 
In addition 10 the homology ""idmt bef"«fl lhe LAr2 lsoforms., prolein scqutT\Ce 
analysIS has r", calcd II COIlscned 40 amHlo acid domain within the N-la-minus of the 
LAPl, ~nn and MAN! inner nuclear proltins and mey ha,e thus been clustered 
10gether to fann 1M LEM domarn pnllcio family (Lin /1 01 .. 20(0). 
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The alpha and beta isoforms have been well characterised and are described briefly 
below. However, not much is known about the gamma isoform other than the fact that it 
is structurally similar to the LAP2~ isoform (Dechat et al., 2000b). 
1.2.2 Functional significance of LAP2a 
cDNA microarray analysis revealed the LAP2a isoform to be up-regulated in cervical 
cancer tissue. LAP2a was initially reported to playa role in processes related to nuclear 
structure, and in nuclear re-assembly following mitosis (Dechat et al., 1998). 
The LAP2 proteins have been shown to interact with a variety of proteins, including the 
lamins, which are important in preserving nuclear structure, as they maintain an 
association between the nuclear membrane and chromatin via interactions with various 
proteins such as LAP2a (reviewed in Gruenbaum et al., 2000). LAP2a interacts with 
lamin A and lamin C which are different splice variants encoded by the lamin A gene 
(reviewed in Gruenbaum et al., 2000). The interaction between LAP2a and lamin A 
occurs via the unique C-terminus of the LAP2a isoform as shown by in vitro binding as 
well as in vivo co-localisation studies (Dechat et al., 2000a). 
In addition to binding to A- and C-type lamins, LAP2a's interaction with chromosomes 
has also been shown. Vlcek et al. (1999) revealed a -350 amino acid region (nuclear 
targeting domain) in the C-terminal tail of the alpha isoform that is necessary for 
association with mitotic chromosomes. In addition to binding chromosomes directly, 
10 
LAP2a also interacts with the DNA·crosslinking protein, barrier·to·autointegration factor 
(BAF), which together have been shown to co· localise to chromatin core structures 
(Dechat et aI., 2004). 
The breakdown and assembly of the nuclear lamina network is essential for cell cycle 
progression (reviewed in Gruenbaum et aI., 2000). It has been shown that LAP2a plays a 
role in nuclear assembly following mitosis (Dechat et ai., 1998). LAP2a's involvement in 
the cell cycle is demonstrated partly by the fact that LAP2a displays differential 
localisation (cytoplasmic or nucleoplasmic) during the process of mitosis and this 
corresponds to alterations in the phosphorylation status of the protein (Dechat et al., 
1998). Three cyclin-dependent kinase sites have been identified within the C-terminal 
region of LAP2a, which are phosphorylated upon entry into mitosis (Gajewski et aI., 
2004). In addition, LAP2a has recently been shown to affect the targeting of A- and C-
type lamins to the nuclear interior, and it has been suggested that this may also affect cell 
cycle progression (Naetar and Foisner, 2009). Conversely, nuclear disassembly and 
chromatin re-organisation are also important events in the process of apoptosis. LAP2a 
has been shown to be cleaved within its chromosome binding domain by caspases during 
apoptosis, thereby preventing its association with chromatin, and allowing disruption of 
nuclear structure (Gotzmann et ai., 2000). 
It has also been proposed that LAP2a has an additional function in regulating 
transcriptional activity. The C-termini of LAP2a and lamin NC have been shown to 
interact with the B and C pockets of the retinoblastoma protein (Rb) (Markiewicz et al., 
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2002). Hypophosphorylated Rb is anchored in the nucleus and binds to the E2F 
transcription factor thereby preventing activation of S-phase specific genes (Mittnacht 
and Weinberg, 1991). Upon phosphorylation of Rb, it is released from the nucleus 
resulting in de-repression of E2F, allowing the transcription of E2F target genes. LAP2a 
has been shown to regulate E2F activity by sequestering hypophosphorylated Rb, 
resulting in maintenance of E2F inactivity (Domer et al., 2006). High levels of LAP2a 
have also been shown to be important in adipocyte differentiation and it has been 
proposed that the LAP2a-Rb complex helps to maintain a balance between the processes 
of differentiation and proliferation (Domer et al., 2006). LAP2a's interaction with Rb is 
further supported by studies illustrating that LAP2a is essential for controlling the 
localisation and phosphorylation state of Rb and that mislocalisation of these proteins 
halts cell proliferation (Pekovic et al., 2007). 
1.2.3 Functional significance of LAP2P 
Unlike the LAP2 alpha isoform, the LAP2 beta isoform contains a transmembrane 
domain and is thus anchored in the inner nuclear membrane forming part of the nuclear 
envelope. A region within the C-terminal tail of LAP2P is important for targeting this 
isoform to the nuclear envelope (Furukawa et al., 1995). It is from this position that 
LAP2P interacts with B-type lamins present in the nuclear lamina (Foisner and Gerace, 
1993). Like LAPZa, LAP2P interacts with the BAF nuclear protein which mediates the 
association between LAP2P and chromosomes in the late stages of mitosis (Furukawa, 
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1999). A solution structure of LAP2~ showed that the LEM and LEM-like domains 
within the N-terminus are important for binding DNA and BAF (Cai et al., 2001). 
The importance of the LAP2-lamin interaction in mediating nuclear assembly in a 
phosphorylation dependent manner was first indicated by Foisner and Gerace (1 993).This 
has subsequently been validated by Gant et al. (1999) who showed LAP2~ to mediate 
chromatin-nuclear membrane attachment and to playa role in lamina assembly. LAP2~, 
together with other inner nuclear membrane proteins, have recently been shown to be 
involved more specifically in the regulation of nuclear envelope formation following 
mitosis (Anderson et al., 2009). Yang et al. (1997) have also shown LAP2~ to be 
involved in nuclear lamina growth in the G1 phase of the cell cycle, thereby implicating 
its involvement in cell cycle progression. 
In addition to its structural role described above, LAP2~ has been proposed to perform 
other regulatory functions within cells. It has been shown to associate with the HA95 
chromatin associated protein, and this interaction has been shown to be important in the 
initiation of DNA replication (Martins et al., 2003). More recently, LAP2~ has been 
implicated in regulating transcriptional activity. This has been shown to be as a result of 
interactions with the germ cell-less (GCL) protein, where together these proteins decrease 
the activity of the DP-E2F complex, resulting in greater transcriptional repression than 
that exerted by Rb (NiH et al., 2001). In addition, LAP2~ has been shown to interact with 
histone deacetylase 3 (HDAC3) inducing the de acetylation of histone H4, and has been 
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shown to repress the transcriptional activity of the p53 and NF-lCB transcription factors 
(Somech et al., 2005). 
1.2.4 Focus of current research on LAP2a and LAP2P 
It is evident that both LAP2u and LAP2P interact with a variety of nuclear proteins 
forming complexes that are important in maintaining the architecture of the nuclear 
lamina during the cell cycle and regulating transcriptional activity (Fig. 1.4); however the 
precise mechanism of how this might occur is still largely unknown. 
The majority of research on LAP2 is focused on the role it plays, together with lamins, in 
laminopathic diseases. This is a group of heritable disorders which are as a result of 
mutations in A-type lamins and other nuclear proteins as reviewed in (Broers et al., 
2004). These include Emery-Dreifuss Muscular Dystrophy, dilated cardiomyopathy (in 
which the LAP2 gene has been shown to contain a mutation (Taylor et al., 2005)) and 
Hutchinson-Gilford progeria. There is however, very little known about LAP2's 
involvement in cancer. 
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Fig. 1.4. &h~ma lic rrp ..... scnlalloo of I h~ ma mmalian nuelear la mina and In ncr 
nnd ra r membranr prote;oli. LAI'2n is indicatcd by the lowe!' arrow Rnd is shown wilh 
its various interaction partno:rs. LAP2n disp lays 8 nuck'<IJIlasmic l()Cali~tion and can 
bind 10 chromosomes via Ihe bamer·to-BulointCW'lltion foctor (BAF) via ils LEM dQJnam 
wilhin illl N-Ienninus as well RS Lllmin NC II!ld the retinohlastoma prolein {Rbi via its 
uni'! ue C'lemlinal lail. I.AP2P is indiCll1ed by the upper afTQW wl><:re its a~socialion ",ilh 
the inner nudear membrane and lamin B withm the nuclear lamina IS shown. lIS 
lIi5OCialion with DNA via BAF IlIId 1-lA9S and the genn cell· less (GCL) Iranscripliona l 
r<:gulalOr IS alSQ higbJig,ll1ed. As Ibis dia~ is r~l'res<:nISli"e of II><: mou);!: nuc leus, the 
LAI>2£: and LAP2,'; homologucs are also inc luded ( Foisnef ('I (II" 2001). 
1.3 T he iuvolwlllen l o f LA- P2 in rllnr(' r 
Express;"" profil ing using mkroarra)'S. pclformed in Out JabornlOl')' has indicated lhal 
cervical cancer paliem materiul disp lays elevated levels o f the all,lw isoform of LA P2 
(van der Wall ('/ al., unpuhlished daUi), LAP2 expression has also been shown \0 be 
associat.:d with eaocer in various olher large·scale genome-wide analyses [Pomeroy .'/ 
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al., 2002), (Yokota et aI., 2004), (Agrawal et aI., 2002), (Welsch et al., 2002), (LaTulippe 
et aI., 2002) and (Rosty et al., 2005)]. There are, however limited reports on the 
validation of this up-regulation in cancer. One recently published paper observed LAP2u 
mRNA overexpression in several primary tumours, namely stomach, breast, larynx, lung 
and colon, where its expression seemed to be regulated by the E2F transcription factor, 
the activity of which is often abrogated in cancer due to dysfunctional Rb (Parise et al., 
2006). Another study reported increased LAP2P expression in neuroblastoma compared 
to normal nerve tissue (Weber et aI., 1999). Expression of the LAP2 proteins in other 
cancer types, as well as the potential role it plays in cancer development remains to be 
elucidated. 
1.4 Significance 
Cancer is a highly complex disease where multiple gene regulatory pathway alterations 
result in tumour cells that can far outgrow their normal counterparts. In cervical cancer as 
an example, HPV infection results in the altered regulation of numerous genes involved 
in important cellular processes, which ultimately leads to the development of the disease. 
An understanding of the changes in genes associated with the development of cancer may 
assist in early detection and treatment strategies. This project aims to characterise a 
possible link between LAP2 expression and cancer. In addition, the identification of 
genes that are functionally relevant to the biology of cancer cells could ultimately pose as 
potential therapeutic targets for the disease. 
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1.5 Aim 
Previous studies in our laboratory which used gene expression array technologies, have 
suggested that LAP2a levels are elevated in cervical cancer patient material compared to 
normal. In this study we aim to explore the differential expression patterns of LAP2 in 
normal and tumour patient tissue, as well as in cell lines grown in culture. The role of 
LAP2 in cancer cells will also be determined by inhibiting its expression in cells in 
culture. The potential for use of LAP2 as a biomarker as well as a potential therapeutic 
target will thus be investigated. 
1.6 Objectives 
1. To determine if LAP2 associates with cancer by, 
(i) investigating expression of LAP2 in cervical cancer patient material 
compared to normal tissue and, 
(ii) determining the expression of LAP2 in normal cells and transformed and 
cancer cells of different origins. 
2. To determine the functional significance of LAP2 to cancer cell biology by inhibiting 
its expression in cells in culture. 
3. To investigate the association between LAP2 and Rb expression levels. 
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Chapter 2: Materials and Methods 
2.1. Cervical cancer patient material 
All cervical patient material was previously collected from Groote Schuur Hospital, Cape 
Town, South Africa (Cancer Biology Group, Medical Biochemistry, UCT). Cancer tissue 
was collected from patients being treated for cervical dysplasia and carcinoma, while 
non-cancerous or 'normal' biopsy samples were collected from patients who were 
admitted for hysterectomies for reasons other than cervical abnormalities. A pathologist 
confirmed either normal or diseased status. All samples were obtained with patient 
consent and the study was approved by the Research Ethics Committee of the University 
of Cape Town (UCT) (REC REF: 153/2004). All cervical cancer samples were identified 
as being HPV positive with 70% of samples infected with the HPV16 type (van der Watt 
et aI., 2009). 
2.2 Tissue cell culture 
2.2.1 Cell lines 
For the determination of LAP2 expression in normal, transformed and cancerous cervical 
cells grown in culture, the following cell lines were used: a normal primary cervical 
epithelial cell culture, HCX, as well as its E61E7 transformed counterpart, HCX-E61E7, 
both of which were obtained from Dr. C. Barker, NIH, USA. Cervical cancer cell lines 
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CaSki (HPVI6 positive), HeLa (HPVI8 positive), ME-180 (HPV68 positive), MS751 
(HPVI8 & HPV45 positive), SiHa (HPVI6 positive) and C33A (HPV negative, mutant 
p53) cell lines were obtained from the American Type Culture Collection (ATCC) 
(Rockville, MD, USA). 
Comparisons between LAP2' s expression in normal and transformed fibroblasts were 
performed using the normal lung fibroblast cell line, WI38, as well as its SV 40 
transformed SVWI38 and gamma-irradiated CT-l counterparts (Namba et al., 1980). 
These cell lines, as well as the CCDI068SK normal breast skin fibroblast, were obtained 
from the ATCC. The FOo normal skin fibroblast was obtained from the Department of 
Medicine, UCT. 
In order to determine the expression of LAP2 in an alternative cancer type, normal and 
cancerous oesophageal cell lines were also used. Normal hTERT-immortalized human 
oesophageal keratinocytes, EPC2-hTERT, were a gift from Prof. A. K. Rustgi (University 
of Pennsylvania, Philadelphia, USA) and were used to compare expression in the 
WHCOI and WHC05 South African oesophageal cancer cells lines (Veale and Thomley, 
1989) and the Japanese-derived KYSE450 and KYSE520 oesophageal cancer cell lines 
(Shimada et al., 1992). 
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2.2.2. Tissue cell culture 
All non-primary cell lines were maintained at 60-80% confluency in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated foetal calf 
serum (FCS) (Gibco, Paisley, Scotland) and 100 units/ml penicillin and 100 /lg/ml 
streptomycin (PIS) at 37°C in a 5% C02 incubator. Cells were sub-cultured with a 0.05% 
Trypsin-EDTA solution and neutralized with DMEM. 
The HCX, HCX-E61E7 and EPC2 primary cells were maintained in Keratinocyte Serum 
Free Medium (KSFM) (Invitrogen, Carlsbad, CA, USA) supplemented with Bovine 
Pituitary Extract (50 /lg/ml for EPC2, HCX and HCX-E61E7) and human epidermal 
growth factor (1 ng/ml for EPC2 and 26 ng/ml for HCX and HCX-E61E7) and 100 
units/ml PIS. The HCX-E61E7 cell line was grown in the presence of 50 /lg/ml of the 
selection antibiotic, G418. Cells were grown to 80% confluency, sub-cultured with 
Trypsin-EDTA and neutralized with soybean trypsin inhibitor. The cells were pelleted by 
centrifugation and re-suspended in supplemented KSFM medium before being re-seeded. 
After sub-culturing, excess cells were re-suspended in cell freezing medium and 
subjected to slow freezing, to prevent the formation of ice crystals. Cells were stored at 
-80°C for two weeks prior to long term storage in liquid nitrogen. 
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2.2.3 Mycoplasma testing 
To ensure that cell lines were not contaminated with Mycoplasma, a microbial 
contaminant invisible to the naked eye, routine testing was performed 2-3 times a year. 
Cells were cultured in PIS-free DMEM for four days before being plated onto coverslips 
and incubated for a further 24 hours. Cells were fixed and stained with the Hoechst 
fluorescent DNA-binding stain before being mounted and visualised on the Zeiss 
Axiovert 200 Fluorescent microscope (Carl Zeiss, Jena, Germany). The absence of 
speckling in the cytoplasm between stained nuclei indicates Mycoplasma-free cell 
cultures. 
2.3 Real-time RT -peR analysis 
2.3.1 RNA extraction 
RNA was harvested from cell cultures at 800A. confluence with QIAzol (Qiagen, 
Valencia, CA, USA) according to the manufacturer's instructions. RNA was re-
suspended in diethylpyrocarbonate (DEPC)-treated dH20. 
2.3.2 RNA quantification 
A 1 :250 dilution of the RNA was made and its absorbance at 260 nm determined on a 
Beckman DU-650 UV spectrophotometer (Beckman Coulter Inc., Fullerton, CA, USA). 
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The ratio of the absorbance at 260 run to the absorbance at 280 run was determined as an 
indication of RNA purity. The RNA concentration was calculated using Beer Lambert's 
Law which states that the absorbance of nucleic acids at 260 run (A) is equal to the 
product of the concentration (~gI~) of nucleic acid (c), the length of the optical path (l) 
and the molar extinction coefficient (s). One A260 unit of single stranded RNA is equal to 
40 ~glml H20 and the optical path length is equal to lcm. 
2.3.3 RNA agarose gel electrophoresis 
One microgram of RNA was electrophoresed on a 1.5% formaldehyde-agarose gel, 
containing 0.5 ~gI~ ethidium bromide, to determine the integrity of the extracted RNA. 
RNA was suspended in RNA loading buffer and allowed to separate on the gel for 
approximately 20 minutes at 65V. Only RNA of a high quality was used in subsequent 
experiments i.e. RNA with a 260 run: 280 run ratio of 1.8-2, a defined 2:1 ratio of 
28S:18S ribosomal RNA subunits and an absence of smearing, indicative of degradation. 
2.3.4 eDNA synthesis 
The protocol for reverse transcribing RNA into cDNA was based on that of van Gelder et 
al. (1990). 500 ng of oligoT7-(dT)2o primer (Promega, Madison, WI, USA) was 
hybridised to 2 ~g of RNA by incubation at 70°C for 10 minutes. A mixture containing 
0.5 mM dNTPs, 5X first strand buffer, 1.5 mM MgCh, 1 ~l of ImProm-II reverse 
transcriptase (Promega) and 40 units of RNasin RNase inhibitor (Promega) was added to 
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each mixture to yield a final volume of20 fll. The mixture was incubated at 42°C for two 
hours. The reverse transcriptase was inactivated by incubating the mixture at 70°C for 10 
minutes. DEPC-treated water was added to yield a final concentration of 0.1 flglfll cDNA 
in a 30 fll volume. Excess cDNA was aliquoted and stored at -80°C. 
2.3.5 Primers 
All primers were designed using Primer-Blast (NCBI) 
(http://www.ncbLnlm.nih.gov/toolsiprimer-blastl) and their suitability tested using Primer 
Express Software (Applied Biosystems, Foster City, CA, USA). mRNA sequences were 
obtained from BLAST (http://www.ncbLnlm.nih.govIBLASTI) and aligned with primers 
using Multalin (Corpet, 1998). Where possible, primers were designed across adjacent 
exons in order to prevent the amplification of any contaminating genomic DNA. 
Cyclophilin (Cyc) and p-glucoronidase (GusB) were used as normaliser genes. Primer 
sequences and annealing temperatures are indicated in Table 2.1. The molarity of all 
primers was calculated using Beer Lambert's Law. Primers were stored as 20 flM stocks. 
Target Forward primer Revene primer ~ 
Cye TGA GAC AGC AGA TAG AGC CAA GC TCC CTG CCA A IT TGA CAT CIT C 
Gusp CTC AIT TGG AAT TIT GCC GAT T CCG AGT GAA GAT CCC CIT TITA 
LAP2a GCA GGC AGA CAT TAG TCA AGC CGA CCT ACA GTG GCA TIT CC 
Rb CACGAATGCAAAAGCAGAAA Gce ATA AAC AGA ACC TGG GA 
Table 2.1: Primer sequences and corresponding annealing temperatures (Ta) used 
in Real-time RT -peR analysis. Primers are shown in a 5' -3' direction. 
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2.3.6 Real-time RT -PCR 
Real-time RT-PCR is a quantitative technique for measuring the mRNA levels of a gene 
of interest, relative to an internal control or housekeeping gene (Houghton and Cockerill, 
2006). Real-time RT -PCR was performed on triplicate samples with 2 J.lI of cDNA (~0.2 
J.lg), or dH20 as a negative control, and 10 J.lM gene specific forward and reverse primers. 
A two-step PCR reaction was followed using the KAP A SYBR qPCR Master Mix 
(KAPA Biosystems, Cape Town, South Africa) using the StepOne Real-Time PCR 
machine (Applied Biosystems). The reaction conditions were an initial denaturation step 
at 95°C for 10 minutes followed by 40 cycles of denaturation at 95°C for 10 seconds with 
a single 40 second annealing/elongation step at the annealing temperature specific to the 
primer set. The SYBR Green I dye intercalates with dsDNA and emits fluorescence 
relative to the degree of intercalation. Amplification is monitored at each cycle in the 
PCR reaction where the cycle threshold (CT) represents a value at which the fluorescence 
is greater than a chosen threshold distinguishable from background fluorescence 
(Houghton and Cockerill, 2006). A melt curve for the PCR products was generated using 
temperatures from 60-95°C to ensure a single product was amplified. 
CT values were calculated in the linear range of the amplification curves generated using 
StepOne Version2.0 software (Applied Biosystems). The .1..1.CT method was used to 
calculate the level of target mRNA expression relative to that of the average of two 
known housekeeping genes, cyclophilin and GusB (Livak and Schmittgen, 2001). 
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2.3.7 Agarose gel electrophoresis 
PCR products were separated via electrophoresis on a 2% agarose gel and visualised by 
ethidium bromide staining. This was to ensure that a single, specific PCR product was 
amplified and to ensure that there was no contamination or primer dimer formation. 
Samples were suspended in 6X loading dye (Fermentas Life Sciences, Burlington, 
Ontario, Canada) and electrophoresed alongside a 50 bp DNA ladder (50 bp GeneRuler, 
Fermentas) at 65V for approximately 1 hour. 
2.4 Western Blot analysis 
2.4.1 Antibodies 
All primary antibodies and incubation conditions used are shown in Table 2.2. Antibodies 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Cell Signaling 
(Beverly, MA, USA) or Abcam (Cambridge, UK). 
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Antibody Type Dilution Diluent Company Catalo2ue # 
p-tubulin polyclonal 1:1000 TBST Santa Cruz sc-91 04 
CDK4 polyclonal 1:2000 2.5%BSA Santa Cruz sc-601 
cyclin D1 monoclonal 1:1000 TBST Santa Cruz sc-246 
LAP2 polyclonal 1 :1000 5% milk Santa Cruz sc-28541 
LAP2a polyclonal 1:1000 5% milk Abcam ab5162 
p16 polyclonal 1:500 0.5% milk Santa Cruz sc-759 
p21 polyclonal 1:250 0.5% milk Santa Cruz sc-756 
p27 polyclonal 1:500 5% milk Santa Cruz sc-528 
PARP polyclonal 1:1000 7% milk Santa Cruz sc-7150 
Rb monoclonal 1:500 5% milk Cell Signaling 9309 
pRb (8071811) polyclonal 1:500 5%BSA Cell Signaling 9308 
Table 2.2: Primary antibodies used in western blot analysis. (CDK4; cyclin dependent 
kinase 4, PARP; Poly (ADP-ribose) Polymerase, Rb; retinoblastoma protein, 
pRB(807/81 1); phosphorylated Rb on serine residues 807 and 811, TBST; Tris-buffered 
saline with Tween20, BSA; bovine serum albumin, milk; fat-free milk powder). 
Goat anti-rabbit IgG-HRP-conjugated secondary antibody (170-6515) (Bio-Rad, 
Richmond, CA, USA) was used at a 1 :5000 dilution in 5% milk and goat anti-mouse 
secondary antibody (170-6516) (Bio-Rad) was used at a 1 :3000 dilution in TBST. 
2.4.2 Protein extraction 
2.4.2.1 Protein extraction from cells grown under adherent conditions 
Cells were grown to 80% confluency in 35 mm or 60 mm cell culture dishes and protein 
lysates harvested in radioimmunoprecipitation assay buffer (RIPA) with a IX complete 
protease inhibitor cocktail (Roche, Mannheim, Gennany) and 1 mM Na3 V04 phosphatase 
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inhibitor. Cell lysates were sonicated for 30 seconds, centrifuged to remove cell debris, 
and the supernatant containing protein stored at -80°C before use. 
2.4.2.2 Protein extraction from cells grown under anchorage-independent conditions 
Cells were plated in 6-well plates coated with 1.5 ml poly-2-hydroxyethyl methacrylate 
(poly-HEMA) to prevent cell adhesion. For protein extraction, cells were pelleted from 
the growth medium by centrifugation at 1000 rpm for 5 minutes, re-suspended in protease 
inhibitor containing RIP A buffer, and processed as described above. 
2.4.3 Protein quantification 
Protein samples were quantitated using the Bicinchoninic Acid (BCA) assay (pierce, 
Rockford, IL, USA) and the absorbance read at 595 nm on a BioTek EL800 (Bio-Tek 
Instruments, Winooski, Vermont, Canada) microplate reader using Gen5 software (Bio-
Tek). The assay is based on the principle that proteins react with copper II to produce 
copper I which reacts with the BCA reagents to form a purple colour at 595 nm (Smith, 
1985). A bovine serum albumin (BSA) dilution series was prepared to produce a standard 
curve which was used to determine protein concentrations of the unknown samples. 
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2.4.4 SDS polyacrylamide gel electrophoresis 
Protein samples at a concentration of 30 j.lg were suspended in 2X Laemmli buffer and 
denatured at 95°C for 2 minutes prior to loading to ensure that the proteins were in their 
native confonnation. Proteins were electrophoresed on a 4% stacking gel and separated 
on either a 8% or 10% resolving sodium dodecyl-sulphate (SDS) polyacrylamide gel. The 
Precision Plus Protein Kaleidoscope Standard (Bio-Rad) was loaded to determine the 
sizes of the resolved proteins. A voltage of 200V was applied for 1 hour. 
2.4.5 Immunoblotting 
Proteins were transferred to a Hybond™_ECLTM nitrocellulose membrane (Amersham 
Life Sciences, Amersham, UK) at 4°C at 100V for 70 minutes. 
The membrane was blocked in 5% fat-free milk powder in TBST for 1 hour at room 
temperature with rotation to prevent non-specific binding of the antibody to the 
membrane. The membrane was incubated with primary antibody, overnight with rotation 
at 4°C. 
The membrane was washed three times with TBST for 10 minutes each to remove 
unbound antibody and incubated with secondary antibody for one hour at room 
temperature with rotation. The membrane was washed a further three times for 10 
minutes each with TBST. 
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2.4.6 Immunodetection 
The specific protein bands were detected by enhanced chemiluminescence. This involved 
the use of the LumiGLO/LumiGLO Reserve chemiluminescent substrate system (KPL 
Inc, Gaithersburg, ML, USA) according to the manufacturer's instructions. X-ray films 
(AGFA CU-BP Medical X-Ray film, Mortsel, Belgium) were exposed to the membrane, 
with the chemiluminescent substrate, for various amounts of time depending on the 
antibody used. X-ray films were developed until the bands could be clearly visualised, 
before being added to a fixative agent. 
2.4.7 Re-probing blots 
Blots were stripped of primary antibody by incubation in 1 M glycine at pH 2.5 for 15 
minutes. The mix was neutralized with 1 M Tris-HCI at pH 8.0 after which the 
membranes were incubated in blocking solution for 30 minutes prior to incubation with 
primary antibody. Blots were subsequently processed as previously described. 
2.4.8 Coomassie staining 
After transfer, the polyacrylamide gels were stained with Coomassie Blue staining 
solution for one hour. A destaining solution was added until the protein bands became 
visible above the background. This technique was used as an additional indication of 
sample loading. 
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2.4.9 Densitometric analysis of western blots 
Following autoradiographic detection of western blots, the band intensity of proteins of 
interest (representative of protein expression) was detennined by densitometry using a 
Chem Genius Densitometer and GeneSnap and GeneTools software (BioIrnaging 
Systems, Syngene, Frederick, MD, USA). Protein expression was determined relative to 
that of p-tubulin. 
2.5 Immunofluorescence 
2.5.1 Immunohistochemistry on archival patient tissue sections 
Tissue sections of -2-5 Jllll from paraffin-embedded sections of 16 cervical carcinomas 
and 9 normal cervical biopsies were used in immunohistochemical analysis. The sections 
were heat-fixed for 10 minutes prior to being re-hydrated and de-waxed in decreasing 
concentrations of xylol and ethanol. Antigen Retrieval was performed by pressure-
cooking the slides in boiling EDT A pH 8.0 for 2 minutes. Slides were subsequently 
washed in phosphate-buffered saline with Tween20 (PBS-T) for 5 minutes and blocked in 
0.2% gelatin in PBS-T for 30 minutes before being washed again in PBS-T and dried. 
LAP2a specific antibody (5162) [Abcam, Cambridge, UK] was added at a 1:100 dilution 
in 0.2% gelatin and 100 J.d of the mix was added to slides and allowed to incubate for 1 
hour in a humidified chamber at room temperature. Slides were washed in PBS-T and 
incubated in 0.3% Sudan Black for 10 minutes to prevent auto-fluorescence. Slides were 
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washed a further two times with PBS-T for 5 minutes and dried before 100 Jil of 
secondary antibody mix was added to each slide. A 1 :300 dilution of Cy3-conjugated 
goat anti-rabbit secondary antibody (Jackson lmmunoResearch, West Grove, PA, USA) 
was made in the 0.2% gelatin blocking solution, added to slides and allowed to incubate 
for 45 minutes in a humidified chamber at room temperature. Slides were washed in 
PBS-T and incubated with 500 Jil of 100 nglml of the nuclear stain 4',6-diamidino-2-
phenylindole (DAPI) (Sigma) in PBS-T for 5 minutes. Slides were washed again in PBS-
T and dipped in dH20 before being mounted in Mowiol 4-88 (CaIbiochem, CA, USA). 
Slides were visualised on a Zeiss Axiovert 200 Fluorescent microscope (Carl Zeiss, Jena, 
Germany) using a Zeiss Axiocam camera and images viewed on Axiovision 4.6 software 
(Axiovision, Gottingen, Germany). Fluorescent intensity was quantitated using the 
densitometric mean of pixel intensity on the Axiovision software. Three fields of view 
were captured per slide, and two regions within each view were selected for quantitation. 
2.5.2 Immunocytochemistry on cell lines 
One hundred thousand cells were plated on ethanol-flamed coverslips in 35 mm dishes 
and allowed to proliferate until 60-70% confluence. The cells were washed with PBS and 
fixed in 4% paraformaIdehyde in PBS for 20 minutes at room temperature. Cells were 
subjected to three five-minute washes in PBS before being permeabilised with the 
addition of 0.5% Triton X-toO in PBS for 5 minutes. The cells were washed again in PBS 
before being quenched with 50 mM NRtCI in PBS for 5 minutes. The cells were blocked 
in 0.2% gelatin in PBS for 30 minutes. Primary antibody was added at a 1: 1 00 dilution 
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for LAP2a (5162) [Abcam] or Rb (9309) [Cell Signaling Technology, Beverly, MA, 
USA] in blocking solution for 45 minutes at room temperature in a humidified chamber. 
Cells were washed 3 times for 5 minutes with PBS. Fluorescently-labelled secondary 
antibody, Cy3-conjugated goat anti-rabbit (Jackson ImmunoResearch) at a 1 :300 dilution, 
or Alexa488-conjugated goat anti-mouse (Invitrogen) at a 1: 150 dilution in 0.2% gelatin 
blocking solution, was added for 45 minutes at room temperature in the dark. Cells were 
washed for 5 minutes with PBS and then incubated with 500 )11 100 ng/ml DAPI in PBS 
for 5 minutes. After a 5 minute wash in PBS the cells were mounted onto slides in 
Mowiol 4-88 before being visualised. For each condition, the fluorescent signal of ten 
cells per field of view and ten fields of view per slide were quantitated. 
2.6 siRNA inhibition experiments 
2.6.1 Transient siRNA transfection 
The expression of LAP2 was inhibited using siRNA specifically targeted to the mRNA 
sequence of LAP2 in order for the effects on cell biology to be determined. Cells were 
transfected with 20 nM of either LAP2 siRNA (h) (SC-43386) or a scrambled siRNA 
sequence Control siRNA-A (SC-37007) to eliminate the possibility of non-specific 
effects. 
32 
2.6.2 Western blot analysis of siRNA transfection 
Approximately 100 000 cells were plated in 35 mm dishes and transfected with siRNA 24 
hours later using TransFectin Lipid Reagent (Bio-Rad). Cells at a confluency of 60% 
were transfected with a siRNA master mix containing a 1:3 ratio of Transfectin:siRNA. 
Per reaction this translates to, the addition of 50 J.ll of serum-free PIS-free media to an 
eppendorf to which 0.625 JlI of TransFectin was added and the mixture incubated for 5 
minutes at room temperature. 20 nM i.e. 2 JlI of a 10 JlM stock of siRNA, was 
subsequently added to the mix, suspended by gentle tapping and allowed to stand at room 
temperature for 15-20 minutes. The media in the culture dishes was changed to 1 ml P/S-
free 10% FCS DMEM and the 52 J.ll Transfection mix was added dropwise to the cells. 
Cells were incubated with the transfection mix for 5-6 hours after which the medium was 
changed to 10% FCS DMEM containing 100 unitslml PIS. 
2.7 Cell proliferation assays 
2.7.1 Cell proliferation assay following siRNA transfection 
The 3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (Sigma 
Aldridge, St Louis, MO, USA) colourimetric assay was used as a measure of cellular 
proliferation. The assay takes advantage of the fact that after incubation of cells with the 
MTT reagent, the yellow tetrazolium salt in the reagent is reduced to purple formazan 
crystals in the mitochondria of living cells. Briefly, 250 000 cells were plated in 60 mm 
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dishes and transfected with 20 nM control or LAP2 siRNA 24 hours following plating. 
Cells were subsequently trypsinised and 2500 cells were re-plated per well of a 96-well 
plate. 1 0 ~ of MTT reagent (Sigma) was added to each well, including media-only 
containing wells, at the appropriate time points after transfection with siRNA. Four hours 
later 100 I.d of solubilisation reagent was added to each well and incubated overnight to 
dissolve the formazan crystals. The absorbance, which is representative of the number of 
viable cells, was subsequently measured at 595 nm. 
For cell proliferation assays at different serum concentrations, cells were plated in 2, 4 or 
10% FCS in DMEM and the MTT assay performed as described above. For MIT 
analysis following serum starvation, cells were plated in DMEM containing no FCS for 
24 hours prior to being plated in 10% FCS DMEM for the duration of the assay. 
2.7.2 Colony forming assay following siRNA transfection 
For anchorage-independent cell proliferation assays, cells were suspended in DMEM 
containing 1 % methylcellulose which resulted in the formation of cell colonies which 
were quantitated as described by Fukazawa et al. (1995). Two hundred and fifty thousand 
cells were plated in 60 mm dishes and transfected with 20 nM control or LAP2 siRNA as 
described previously. Twenty thousand cells were subsequently re-suspended in 100 J.lI 
1 % methylcellulose (Sigma) in 10% FCS-containing DMEM and plated in quadruplicate 
per well of a 96-well plate. Each well had been coated with 100 J.lI of poly-(HEMA) 
(Sigma) 16 hours previously to prevent cell adhesion. Colonies were monitored for eight 
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days post transfection at which stage they were stained with 1 mg/ml p-iodo-
nitrotetrazolium violet (Sigma) overnight at 37°C. Colonies were photographed by 
brightfield microscopy at 400x magnification using the Moticam 2500 camera (Motic, 
British Columbia, Canada) on a Zeiss Telaval microscope. 
2.8 Drug sensitivity 
2.8.1 leso determination 
The IC50 for 5'Fluorouracil (5'FU) was determined in CaSki cells using a range of 
concentrations (0,0.1, 1, to, 25, 50, 100 and 200 JiM). Ten thousand cells were plated in 
quadruplicate in 90 ~ in 96-well plates and treated with 10 Jil drug diluted in DMEM and 
dimethyl sulphoxide (DMSO) (Sigma) to give a final DMSO concentration of 0.2%. 
Cells were incubated for 48 hours, after which MIT and solubilisation solution was 
added to determine cell viability. Data was analysed in GraphPad Prism to determine the 
IC50 of the drug. The 1Cso of 5 'FU in CaSki was determined to be -1 JiM which was used 
in all further drug sensitivity experiments. 
For cisplatin (CP) in CaSki, the optimum concentration resulting in -50% cell death was 
experimentally determined to be -86 nM. 
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2.8.2 Drug treatment following siRNA transfection 
Two hundred and fifty thousand cells were plated in 60 nun dishes before being 
transfected with 20 nM control or LAP2 siRNA as described previously. Ten thousand 
cells were subsequently plated in quadruplicate in 96-well plates and treated with 1 J.lM 
5'FU or 86 nM CPo Cell proliferation was measured 48 and 96 hours post drug treatment 
using the MTT cell proliferation assay as previously described. 
2.9 Cell cycle profile analysis 
2.9.1 Anchorage-independent cell cycle analysis following siRNA transfection 
The cell cycle profile of cells was determined following staining with propidium iodide 
which allows DNA distribution histograms to be plotted on the basis of the DNA content 
of a cell where n = the number of chromosomes in a non-dividing cell and 2n = the 
number of chromosomes following DNA synthesis (Krishan, 1975). Three hundred 
thousand cells were plated in 60 nun dishes and transfected with 20 nM control or LAP2 
siRNA as previously described. Cells were re-plated on poly-HEMA-coated 6-well plates 
24 hours post siRNA transfection. Wells were coated with 1.5 ml poly-HEMA 16 hours 
prior to plating. Cells were harvested four and eight days post transfection. Cell-
containing medium, together with two PBS washes, was collected in 12 ml tubes. The 
cells were pelleted by centrifugation, re-suspended in DMEM and counted. The cells 
were fixed by the addition of 100% ice-cold ethanol and incubated at -20°C overnight. 
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Cells were removed from the ethanol by centrifugation at 1000 rpm for 5 minutes. The 
cell pellet was washed twice with PBS. 0.5 x106 cells in PBS were aliquoted into 
eppendorfs and centrifuged at 1000 rpm for 5 minutes. RNase A (Fermentas) diluted in 
PBS was added to yield a final concentration of 50 J.lglml in a volume of 200 J.ll. The cell 
mix was incubated with the RNase A solution at 37°C for 15 minutes. Twenty minutes 
prior to FACS analysis a 0.5 ml 0.01 M propidium iodide (PI) staining solution was 
added to each cell sample. 50 000 events were analysed using a F ACSCalibur (Becton 
Dickinson BioSciences, San Jose, CA, USA) using CellQuest software to generate the 
cell cycle profile. The data was fitted to cell cycle profile models using ModFitLT 2.0 
(Verity House Software, Topsham, ME, USA) and FlowJo 6.0 software (Tree Star Inc., 
Ashford, OR, USA). The Dean-Jett-Fox model was used to determine the cell distribution 
[(Dean and Jett, 1974) and (Fox, 1980)]. 
2.10 Apoptosis cell death assays 
2.10.1 Caspase 317 activity assay 
Caspases are known mediators of the apoptotic pathway and thus the activity of these 
enzymes can be determined using a luminogenic substrate where the luminescence 
produced is proportional to caspase activity and thus apoptosis (reviewed in Nicholson 
and Thornberry, 1997). Two hundred and fifty thousand CaSki cells were plated in 60mm 
dishes and transfected with 20 nM control or LAP2 siRNA as previously described. Cells 
were incubated for 24 hours after which 20 000 of the transfected cells were plated in 
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quadruplicate per well of poly-HEMA-coated 96-well plates. Seven days post siRNA 
transfection, cells were harvested from the medium, pelleted following centrifugation and 
re-suspended in 80 ~ cell culture medium. Twenty microlitres of this mix was 
centrifuged and re-suspended in RIP A, and a BCA quantitation performed to determine 
protein concentration. Sixty microlitres of the Caspase-Glo® 317 assay buffer (Promega) 
was added to the remaining 60 III cell mix and incubated at room temperature for 1 hour. 
Samples were transferred to white plates and luminescence quantified on a GloMax 96 
Microplate Luminometer System (Promega). 
2.10.2 Poly (ADP-ribose) polymerase (PARP) cleavage assay 
PARP is a known in vivo caspase substrate (Nicholson et al., 1995), and thus cleavage of 
this protein into two detectable fragments is representative of cells undergoing apoptosis. 
Two hundred and fifty thousand CaSki cells were plated in 60 rnm dishes and transfected 
with 20 nM control or LAP2 siRNA as previously described. Cells were incubated for 24 
hours after which the cells were trypsinised and plated on poly-HEMA-coated 6-well 
plates. Seven days post siRNA transfection cells were harvested from the medium, 
pelleted following centrifugation and re-suspended in 50 III RIPA. Lysates were 
quantitated and subjected to western blot analysis as described previously. The presence 
of a smaller 85 k:D band, in addition to the 116 k:D full length P ARP band, is an 
indication of apoptosis. 
38 
2.11 Cycloheximide protein stability assay 
Cycloheximide (CHX) is a protein synthesis inhibitor and it can thus be used to measure 
protein degradation and protein half-life as a measure of protein stability. One hundred 
thousand CaSki cells were plated in 35 mm dishes and transfected with 20 nM control or 
LAP2 siRNA as described previously. Cells were incubated for 48 hours and then treated 
with 50 J.lglml CHX (Sigma). Protein was harvested at 0, 3, 6, and 12 hour time points 
following CHX treatment and Rb levels analysed by western blot analysis as previously 
described. Rb and p-tubulin expression was determined by densitometric analysis of the 
western blot band intensities using a Chern Genius Densitometer and GeneSnap and 
GeneTools software. Densitometric values for Rb and l3-tubulin were calculated relative 
to Day 0 and log values plotted against time. A linear trendline was fitted to the data 
points. The half-life of Rb was calculated using the following equation: tI/2 = 10g2/m 
where m = (y-c)/x on a linear graph. 
2.12 Statistical analysis 
All experiments were performed in triplicate and repeated at least two times. Results are 
presented as the mean value ± standard deviation unless stated otherwise. The Student's 
I-test was applied to calculate statistically significant differences between samples. A 
two-tailed distribution was used and, either equal variance was used for matched treated-
untreated samples, or unequal variance was used for unmatched samples. Statistical 
significance was defmed using a type I error or p-value of 0.05 where the p-value is the 
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probability of rejecting the null hypothesis when it is assumed to be true. All calculations 
were perfonned in Microsoft Excel and GrapbPad Prism (GrapbPad Software, La Jolla, 
CA, USA). 
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Chapter 3: LAP2 expression in cancer lind tr3n SrorOlrd cells 
3. 1 Introduction 
Cancer research is primarily lIPproached from three an!,:l\!>; namely; the early detection of 
the disease. the prevemion of its o«urrence and lreatment development for p31icn1s who 
have contracted the disease, The idenlilkation of biomarkers asSlXilited with the disease. 
has an Importllllt role 10 play throughout Ihe process of CanCer progression and has the 
polcmial for I'>oth diagliO'ltic lind prognostic value (DiB!:Jllm 3 I). 
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Diag .... '" 3. 1: Sch"malic reprts<'Dla tion of cancer dtvelopnwnt and the potential rol .. 
of biomarliers In tnl t liing Ihe di~eau', (Srin iv8s el a/ .. 2(01). 
The Identification of biomarker1l In diseases sueh as cancer IS no", an cMabl"hcd arca of 
research. The National Cane ... institute (N IH. USA) defines hiomll rkers as biological 
moleeules foulld In the body, ei lhe. on hody fl uids, or in tissue seclil'1Il<, lhal are a s,gn of 
a nonnal or abnonnal process. or of a condieion or disease. Arguably. the most well 
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known example of a cancer biomarker is the Prostate Specific Antigen (PSA) identified 
in 1980 (papsidero et ai., 1980). This protein has been shown to be released into 
circulation at high levels during early stages of prostate cancer development and to even 
greater, quantifiable levels in late stages of the disease, and has thus been used as a 
tumour biomarker for diagnosing prostate cancer. 
Alterations in gene expression are known to be fundamental events in cancer progression, 
and form one of the processes responsible for an accumulation of biomarkers in the 
cancer state (K.ulasingam and Diamandis, 2008). One of the main goals of our research is 
thus to determine whether proteins, which are shown to be overexpressed in cancer tissue 
compared to normal, can pose as potential biomarkers for identifying the disease 
condition. Expression profiling experiments, performed in our laboratory, identified a 
range of differentially expressed cDNA transcripts in cervical cancer tissue compared to 
normal tissue, one of which was recognised to encode the LAP2a protein (van der Watt 
et ai., unpublished data). Similar genome-wide studies have also suggested an association 
between increased expression of the LAP2 gene and cancer. Expression profiling 
experiments have shown increased expression of the LAP2 gene in medullablastoma 
compared to normal cerebellum [(Pomeroy et ai., 2002), and (Yokota et ai., 2004], colon 
cancer tissue compared to normal mucosa (Agrawal et ai., 2002), and the LAP2 gene has 
been shown to be regulated by the BReAl oncogene in breast cancer (Welsch et ai., 
2002). LAP2 has also been implicated in cancer progression, as its expression was found 
to be elevated three-fold in metastatic prostate carcinomas compared to primary prostate 
carcinomas (LaTulippe et ai., 2002). LAP2P has been shown to be highly expressed in 
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neuroblastoma cell lines and has been postulated to be a potential tumour marker (Weber 
et al., 1999), while one study has shown overexpression of LAP2a in larynx, lung, 
stomach, breast and colon primary tumours by quantitative RT -PCR (Parise et al., 2006). 
While the LAP2 alpha and beta isoforms differ in their C-termini and localisation, both 
isoforms are important in: maintaining nuclear architecture through interactions with 
nuclear lamins (Gruenbaum et al., 2000), facilitating post-mitotic nuclear assembly, 
(Vlcek et al., 1999) as well as regulating transcriptional activity through interactions with 
Rb (LAP2a), HDAC (LAP2P) and GCL (LAP2P) [(Markiewicz et al., 2002), (NiH et al., 
2001) and (Somech et al., 2005)]. These proposed functions may be enhanced or 
abrogated in the cancer state as a result of LAP2 overexpression. 
To our knowledge, no other studies have validated LAP2 overexpression in cervical 
cancer. Two approaches have thus been used to determine LAP2 expression in 
transformed and cancer cells. Firstly, biopsy samples from cervical cancer patient tissue 
material were assayed for LAP2 expression levels by Real-time RT-PCR analysis and 
immunohistochemical techniques on archival patient tissue sections respectively. 
Secondly, LAP2 protein levels were determined by western blot analysis in cultured 
cancer and normal cell lines. 
In addition to investigating the expression of this gene in cervical cancer, its role in 
oesophageal cancer was also examined. Oesophageal cancer is the eighth most common 
cancer worldwide (Kamanagar et al., 2005) and is the second most common cancer in 
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black South African males (Mqoqi et al., 2004). Oesophageal cancer, like cervical 
cancer, is often only detected in the late stages of the disease and thus often results in a 
poor prognosis (reviewed in Tew et ai., 2005). 
In order to determine whether LAP2 associates with cellular transformation, LAP2 
expression in transformed cells in culture was also determined. Transformed cells are 
similar to cancer cells in that they display altered gene expression patterns and exhibit 
malignant properties, however they are not derived from in vivo cancers but are generated 
in vitro through the use of transforming agents such as viral oncoproteins and ultraviolet 
radiation. LAP2 expression in normal cell lines, which undergo a limited number of cell 
divisions due to their inability to produce telomerase and their susceptibility to contact 
inhibition, was compared to transformed and cancer cells that replicate indefInitely as 
they do not undergo contact inhibition but form foci on cell culture plates. 
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3.2 Results 
3.2.1 LAP2a expression in cervical cancer patient material 
3.2.1.1 LAP2a mRNA expression in normal versus cervical cancer patient specimens 
Tissue biopsy samples were collected at Groote Schuur Hospital from patients with 
cervical cancer. as well as from patients who have had hysterectomies for reasons other 
than cervical dysplasia, hereafter referred to as 'normal patients' (Cancer Biology Group. 
Medical Biochemistry, VCT). RNA was extracted, complementary cDNA synthesized. 
and expression profiling using cDNA microarrays performed to determine the differential 
expression of genes in cancer compared to normal (van der Watt et al., 2009). One of the 
cDNA transcripts identified to have altered levels of expression in the cancer samples 
compared to the normal. encodes the LAP2a. protein (Fig. 3.I.A). Increased LAP2a. 
expression was confirmed by performing Real-time RT-PCR analysis on RNA biopsy 
samples using primers targeted to the unique C-terminal tail of the LAP2a. isoform. 
Sixteen cancers and nine normals were analysed for LAP2a. expression relative to the 
Cyclophilin and p-glucoronidase genes which are routinely used as internal controls in 
quantitative RT-PCR experiments [(Valente et al .• 2009) and (Shih et al .• 2002)]. The 
average expression of these two genes was used to normalise LAP2a. expression, as the 
use of multiple genes as internal controls for Real-time RT-PCR has been shown to 
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Figure 3.1: Relative LAP2a mRNA levels in normal and cancer cervical tissue. 
(A.) LAP2a. mRNA expression determined by Microarray analysis (normal; n = 8, 
cancer; n 16) (van der Watt et al., unpublished data). (8.) Relative LAP2a. mRNA 
expression was determined by Real-time RT-PCR analysis (normal; n = 9, cancer: n = 
16). GusB and cyc10philin were used as normalisers of the data. Results shown represent 
the mean ± SEM (*, p-value <0.05). 
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increase accuracy (Vandesompele et ai., 2002). Results obtained confIrmed the initial 
microarray studies indicating that there was approximately a 2.5-fold increase in LAP2u 
mRNA expression levels in cervical cancer patient material compared to normal cervical 
epithelial tissue. This corresponded to a statistically signifIcant difference in expression 
(Fig. 3.l.B). 
3.2.1.2 LAP2a protein expression in normal versus cervical cancer patient 
specimens 
Having established that cervical cancer tissue displayed elevated levels ofLAP2u mRNA 
expression, the next step was to determine whether this up-regulation was evident at the 
protein level, as it is proteins that form the functional units within cells. Paraffm-
embedded cervical tissue sections (normal and cancer) were obtained from Groote 
Schuur Hospital and the Department of Anatomical Pathology, UCT, for 
immunohistochemical analysis. Sections were incubated with a LAP2u specifIc primary 
antibody and a Cy3-fluorescently-Iabelled secondary antibody, as well as the DAPI 
nuclear stain. Images were captured using phase contrast microscopy to reveal tissue 
architecture, and the Cy3-fluorescence channel was used to determine the intensity of 
LAP2u staining. 
Phase contrast images from sections derived from normal cervical tissue revealed typical 
stratified squamous epithelial tissue present in the cervix (Fig. 3.2.A). Basal epithelial 
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Figure 3.2: LAP2u pro lein npress[on In normallnd cancer ren·k ll liuttl'. 
tA.) Reprcsenul.liw.: LA['2u prolein expression in archival lis~ue SlX'lions shO\\T1 by 
immuoolluorescence II-here LAI'2a expression is detected In the CyJ channel end DA!' I 
r"pn:sems cdl nuclei . 2° Ab con lrol (secondary antibody comrol ) has 00 LAP20 primary 
amibody lind is shoo\\"n as an indication of the specificilY of the OllOrcscemly taggi:d 
secondary antibody. II) Secuon from nonnal cervical tissue. b) Section from "",rvica! 
cancer 1issue. c) Section from cervic~1 cancer 1issue \\"ilhoul pnmary antibody stain ing. 
All images wen: capturL-d II 400x magnification using the :.;arne eXJX>surt time. Phase 
contnl5t images were captured 10 show lissue architecture. (E: epithehum. S: stroma. L: 
lumL"/l). (8.) Qunntilalion (If LA f'2a exprcssion in nomlB! 8I1d can.cer lissue sections. 
(normal: n ., 9. cancer; n - 16) QU8l11ilaiion \\"as d.:tennincd usmg Aximision 4.6 
sof\lI·arc ond on average of six fields of view per slide were analysed. Resul1s shown 
reprcsem lhe mean ,j, min imum and maximum value$ (-, p-value <0.05). 
cells. "hleh ~ prol iferating eells. rt'Side on the basement membrane which 
sepIlnIu:s!he epi lhd ialla)'cr from the stroma. A.J; edl ru\"lsion occurs. these o: lIs bc8l1l to 
differentlale t8ll5Ulg them to nallen before bemg sloughro otT into the lumen of the 
Ct1'V1X (Fig. J.2.A panel a). Corresponding images from sections derived from c:ancer 
patients showed abnormal cells throughout the tpllht li.l la}"C1'" IS wcll lIS poehtJ of 
IIlfihlllt tng e~ncer cclls .... ithin the stroma (Fig. 3.2./\ panel hI. LAP2u displayed high 
CXprt'SSIl)n in the tp,tho:lial -deri\"cd cancer cells. and III expression was vis ible eom~red 
10 that in the surrounding Slromal lissue, ".,melt shQwed lillie SlaininlJ.. In contr.SI, very 
low lc\"tls of LAP21l slaminil were delecled within nOrmlll cCTVical t issue setlion •. A 
section incubatlld wit!:. secondary anlibody .Ione. lIS a negalive oontrol. confirmed that 
the lIuorescem signal "bl.moo Wail specific 10 LAP20 SlainiD!; (Fig. 3.2.A panel c). 
QlI;Inlificalion of the I AP2a nuore5CCnl imensil) in six trcn canccT and nux nonnal 
SCICI l0ns re' ealcd un tncrease III LAP2(o protein exrression levels in the cancel" $JIClC imens 
(Fig. 3 .2.B). Th,s c<>r\\!_<fM'ndcd tn In appll'ximatc t"'n-fold increase in LAPla c.~pt'"t'$$ion 
m cancer oompand 10 normal. An 111"\'1 comprisiDg IOIlghly tc1\ cclls per view was used to 
measure the fluorescen t inU:nSIIY (dcnsllomnric iDten5iIY 'cm1) of LAP20 mirung in the 
diffm:m ~ions. The nuorescent intCllSlty per slKle WI5 calcu lated 011 IIx basis of six 
fields of view using Alliovision soft ... ·III'C. 
Th~ rcsulls further $IIpponed the micro&lny and Real-ume RT-I'CR data. and showed 
\hal. LAP2G displayed elcvated le,,~ l$ of expression UI lhe rnRNA and prole'n levels in 
cervical cancer trssue· specimens compared to IIOmla l. We 11<:111 ;Iw<:stigated LAP2(l 
cxprt'SSion kIds In 1:<:11$ in cullure. 10 dclcnninc 1.A1'2u ,,~~ssion In caro.:o:r Dnd 
transfonned cell lines of different types. 
3.2.2 LAP2 upressiou in cullured cells 
1.2.2.1 Western blo I IDa]~'5h of LAP2 nprHsloo 
A panel of cervical cancer cell linC1l (CaSki, Hel a. SiHa. ME·] 80, MS751 lind C33A) 
was used 10 compare C};llression of LAna to that in. nMmal primary cervie.l qlilhcliai 
~cll cuhure. HCX, and ,IS lrnnsfurmed oounlerparl ~ICX,E6IE7, which has been 
Irlln,f~'mll-d by Ihe HI'V encoded E6 and E70ocoprolcinll. 
1.AJ>2u expn:s.o;ion was Iklennincd using proteins elllracled from Iltese cell lines and III 
Illtibody IMI targels the uruquc C-tenninal Illil of lhe alpha iJIIDfonn. W~rm blot 
analysIS reluled higher LAP!a expression in the majonly of Cantt'T cell h~ rompar\'d 
to 11M: nonnal pnmary ceo'ical .:pilhehal cell caltaR" (Fig. 1.l,A). The CllA, HPV 
~1I1·e. cdl Imc displayro the smalkst ino;:rt:a5e in !..AI'la ClIpn::SlilO11 compared 10 
HeX fl-tubuhn " '115 shown as a loading control to clIdudc thaI diffcrmco:s ot.scned may 
hll'" been IS I result of differences in \he amount of protein analysed. Dt:osllom,'tnc 
anal)'Sis of 11M: "",,stem blut band in lensil) qUlllltiuut-'ely !JtOlll'd the increase in LA 1'111 
clIpl"C!lliiun III cen'ical cane",," <;:eHs (Fig. 1.3.8). lnterl.'Slingly. an DPllTollinune \wll· fold 
Increase in LAJ '2u expressilm WKS observe<! in dll,' HCX.E6fE7 lnHlsfomled human 
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~'igu", JJ: LAP2a Ilrol~in n:presion in n'o-jell ' CII ncer ct' ll line!!. 
Pro .. ~in 1)'51u!s from roormal and cancer cervical cell lines I'ttt anaJ)"'Sed by ",1:"1.'I'J1 bIOI 
analys'J . CA.) WeslC'TTI biOI !ohowing inerea§cd LAP2u cxpreloSion In cancer cell 'inu 
\lslnS _ I..AP2 .lp .... -spccirlC antibody. ~Iubulin was included as a control for protCln 
loading. (8 .) Quant itotion of LA p2a c:<pressioo r'dati,'C' 10 JJ-tubulin lku:rm incd by 
<knsnolllctry of "C'St1.'l'J1 biOI band imcltSn ), using GcneTools $Of'tw",.c. Res ... 1ts are 
~nlali,c ofc.'(p::rimetlLS performed II kast l'IiO indcpm!lcml times. 
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cervical epilhella l cells compared 10 Ihe nonnal control cells {HeX). 5uggestinK thaI 
I..AP2a may al;social~ "1lh cellu lar Inmsfonnalion. 
A pan·I..AP2 a!wibody thaI I"CCQgniscs Ille common N·lenninal reg.kln of all Ihree human 
isofQnT1S of LAP2 was al so used 10 delerm in~ wooller Ihe same increase could be' 
observed (Fig. 3.4.A ). The lOp band r~"pr=:."II15 lhe 75 kD alpha isoform of I..AP1, Ille 
midd le band Ihe 55 kD bela isoform. and the lower band the 39 \ill gamma lsofonn. The 
aJpba anJ bela isofonns s..-.:med 10 be the predomimul1 LAP2 isofonns. while the gamma 
isofQnn was bardy deleClabie in mGSl cel! lines. and was "in uall y absem in the CaSki 
edl tioc. There was increased LAP20 e.xpression in lhe majority of caneer cell tines used 
as previously shown "mh Ih¢ alpha,spoXilic antibody (Fig. 3.4.A and B). Im~reSiingly. an 
increase in th¢ c.\pres<;ion of the LAP2P isofonn "''35 also observed. BOIh LAP2!.! and 
LAI'2P (herealkr referred to as L-\P2) expression was also incrcascd in the IIPV E7· 
lransfonncd cell line compared to the normal primary c"I"-';c.:1I cpnhclial. HCX cells. 
To funh"r in\"c;ligale til e possibili ly Ihal LAP2 ass-ocinlcs wilh ce llular lransfofIlUltion. 
ils e"pression in nonnal and transfonn~-d fibroblasts W aS dL'Icrmined. I..AP2 expression in 
normal breast skin fibroblasts. CCDI068SK. normal skin fibroblasts. F~ and nonnal 
lung libroblJisls. W13S. was compared 10 Ihal in the SVW138 and CT- J lransformod lung 
tibroblasts. LAP:! was barely detectable III CCDI068SK. FGo and Wl38. The 
lransformed fibrobla5ls showod substantiall y highl:r LAP:! levels comparoo to nonnal 
fibroblasts as illustrated by wcstern blot analysis (F i", 3.5.A) moo dms.llOrnctric 
quantification ofwcslcrn blots (Fig. 3.5.8 ). 
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F1I!1U~ 3.4: LAP2 prolcln uprtuion in UI"\"iu l unttr cdlllnts. 
Protem l)'$llle!! from normal and c;ancn (;11:1'\ ic:,1 <::ci l linl'S WCr'C a",!lysed by \H$l~'TlI biOI 
analYSIs_ IA.I The: upper p&III:l soo\\'s 1M ellpn:sslon of all tllree LAP2 i50fomu; 7j 1.:0 
alpha ;l\O;Iform. 5S U> bet_ tMfom! 800 1M 39 Id) gamma i50r."m usln ll an anllbody thai 
reoogruscs the o;t:onulI('f1 N·ICTminal tail uf.1I three isof<)Olls, LAI'2u ilfld LAP2P sho" 
higher prolein expressIOn in cervical cancer cd l lines (CaSki. 11cla ME-ISO, M$751 , 
StHa) compared 10 the normal <::ervK..l ~jlhehal cell lilll: He X and tlo.c IICX· I:.6fE7 
t11lllsfc.nnro ."itheli,l «- II lioe. jl. lubu.hn \.,as included Il.' a c(JfIlroi for prolem lo3dini!:. 
(S.l Quanmation of LAf'2a and LAP2P t>.pl'l:SSion ",Iath-c 10 II-Iubulm determined by 
demllometty. ResultS ore rqI'r5enUlI,,"c of cxpenmenu ""rfonned al least 11"0 
irKkpnJdcnI lime$. 
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Figuf'C' 3.5: LAP2 protein t'xpreuion in nnrmalaud transformed ribrohl.nt crllllnl'$. 
(A.) Protein [}'Sales from !lOnna! arxl trans rormed fibroblasts .... ere subjected 10 ,,?estem 
1>101 analysis for LAP2 expression. LAP2 shows IlIgher e~l'resslon in transformed lung 
fibroblast cell lines (CT·! and SVWI38) compared to II()ffi1IIl fibroblasts (CCDI068SK 
(brca:;!.). FGo (skin) lind W138 (lung» . (B.) Relative LAI'2u and LAP2P el'pression ill 
fibroblBst cell ti nes del ermined by densiton>Ctric analysis of LAP2 and I3-tubulin western 
bioI ba,td illlimsily. Resu llS are representative of exptTimems performed al lcus! two 
independent times. 
Increased LA P2 expressIon thus 3.ppeaN 10 ISSOI:iale 'Nuh both cervIcal cancer cell linl'S 
and InmsfomH",1 fibroblul~. We ""~ thtTefOl'"e IMt:rc:SlOO in determining whcther this 
expmsion pallern is unique l(l cno. ica l cancer. 01'" whelheT iI OCCl,lrs in (tther Cjjn<.!er 1ypc"S. 
An in'~"St igation of LA P2 e.x.~ was thl,l'S al", performed in a panel of oesophageal 
canc~r cell lirlt!$ (WHCOI . WHCOS, KYSE45Q and KYSES20j and. compared to the 
COITL'SJIOnd inS nonnal o.:lOphageal cpnheh31 cell line EPC2. As OOSCTved WIth nonnal 
CCT\iicBI epithelial and normal fibroblast', LAP2 expression was shown to be very I"", in 
the normal epnhelial oesopIulgeal cells, wIth hIgher ~xpR"ssion levels observed 111 the 
cancer cell li nes (Fi;. 36.A and FiB. 3.6.8 t. TDk"ll together. th""" ri."",,11s suggCSl the 
increase in LAn OPf"C5slon lUOCialCS wnh cellular Il"3n~rOnnatlon. as " ell as "ilh 
cancer cells of dilTem1l origill!l 
3.2.2.2 I m munO<"yl<xhe'n i f~ 1 ~n~l,·sis of I.AP2u c~Wt'S5ioll 
T1lc iucrnsc: In LAP2u expn:ssion in Inmsfonm-d IIIld cancc-r <"4:11 linc-s was 
ioocpeoo",,-Iy oonfinned using immunocytochemistry Pafllfonnaldc:hyde-fill:ed cells 
were IIlCubated ",ilh a LAP2n specific antibod) which is reoognl$Cd by tbe Cy3·IDbcll~d 
secolldary antibody. as '\~ II as a DAPI nu<:lear stain. TI>e hii:~t el<pn!Ssioo of LAP2n 
IOU obs<:l"\'ed in the CaSk, cervical cancer cell line and lhe SVW138 ImnsfQT1T1cd 
fibrobiasl cell line. while Ihe I10Imal WI38 te ll line displayC"d 10WCT 10·e15 of I..AP2u 
(Na- 3.7.A). nle mc~ image gl':nmtcd from 1],( DAPI Ind C)3 (showin!! I..AP2n) 
channel, inditaled Ilud l-ar IOCIIliSllIKHl (If LAP2u u I':Apctied from pm;iou! published 
n.'JIOIU 011 LAP2u local isalion (I)e;:hat 1'1 Di., 1998) The fluorescnll iplensil) of LA 1'20: 
$Iaining was calculah:d in the dilTC'r"ent cell IIf\tj ." here Il':n cells per field of view and tcn 
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(A.I ProcCID lysalCS from normal and clncer oc'SOphagelil tell lines were Albj<:l:lcd In 
western bioi anll)"'S;s for LAP] cxp~ion. LAP] sbows sigrufocan!ly higJHor expression 
In ()I:$Opl\;lgt"lli cancer cdl hDi:li {WIKOl. W!iCOS. KYSE450. KYSE520j compared 10 
1M nonnal 1nlloonlll iscd ocsoplt_gclIl <;dl line EPC2. (8.) QuanlllallOn of LAPlu and 
LAP2P txpreMioo relative 10 jl-lubulio in oesophageal cell lines. Protein expression was 
dC1cnnmcd by dcruilOmctry OfWO!StCTn bLot band intcnsl1Y. Resuhs.", «:prcs..--nt8t;IIC or 
e1Ipl"limC'l1ts perf,,~-d at kullwD ind .. p.,",,,,,,,, times. 
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Fig ll rt' 3.7: LAP2u n pre:ssion In Y norm~ I. , r ons formed w nd ClI ne!.'r ce ll li ne. 
IA.) Immunof1oores<.:em analysis in Ihe normij! fibmblaSl, WJ3S, transformed fibrobla$!, 
SVW1JS, and CaSk! cCTVlcal canceT cell Jines. Images were eap,"roo using lOOOll 
mallDificatioo and the sallie e~posuK time was used IICrt'lSS all samples. 
Immlll10 nllor~C'Ilcc shows lhe nudear locaJisa,ion of LA P2a expression. lB.) 
QlIIIlllil&lioll of LAP2u ~presslon in WiJS. SVWIJS and CaS!.:i cell hnes. Fluorescenl 
inlens;l), was calculaled using Alliovision soft ware where 10 cell s per lidd of view and 
!O fields of view wcrt' quantitatfil pn slide. Ollanlification of LAP2u cXflCe$sion was 
thus obtained from al leaS! 100 cdls peT colldition. Results 8J'C represenlali vc of 
cllpcri menls pl:lfomled 31 leas, twO indepcndem limes. (., p.vmlue <O.OS) . 
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fields of view per slide were quantitated as described previously. A significant increase in 
LAP2« fluorescent intensity was observed in the transformed and cancer cell lines 
compared to normal fibroblasts (Fig. 3.7.B). These results support the western blot data 
suggesting that increased LAP2« expression associates with cellular transformation and 
cancer cells. 
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3.3 Discussion 
This study aimed to follow up on expression profiling data that identified genes that are 
differentially expressed in cervical cancer patient material compared to normal, as 
potential biomarkers and cancer therapeutic targets. Identification of cervical cancer 
biomarkers could potentially enable diagnosis, or predict prognosis and patient response 
to therapy, and hence potentially reduce mortality rates associated with the disease. 
The focus of this study are the LAP2 proteins, where the alpha isoform was found to 
display increased expression in cervical cancer patient material compared to normal 
tissue, by expression profiling experiments using cDNA microarray analysis. Microarray 
data should be independently validated using alternative techniques as there are often 
cases of false positive and false negative results. This present study confirmed an increase 
in LAP2u mRNA and protein levels in cancer tissue compared to normal tissue as 
suggested by·microarray analysis. A similar trend of increased LAP2u expression was 
also observed in cervical cancer cell lines compared to a primary normal cervical 
epithelial cell line. Interestingly, western blots also showed an increase in the LAP2~ 
isoform, while LAP2y levels were largely undetected. Higher LAP2 (LAP2u and LAP2~) 
expression was also observed in transformed fibroblast cell lines and suggested that 
LAP2 expression is associated with cellular transformation. LAP2 was also shown to be 
overexpressed in oesophageal cancer cell lines compared to normal, suggesting that 
LAP2 expression associates with multiple cancer types. 
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A possible explanation for the observed up-regulation of LAP2 in cervical cancer, as an 
example, could be due to enhanced E2F activity in cervical cancer cells as a result of 
diminished Rb function. Rb is sequestered and targeted for degradation by the HPV E7 
oncoprotein resulting in the activation of the E2F transcription factor (Bosch et at., 2002). 
This allows for the increased transcription of E2F target genes. As LAP2 has been 
reported to be regulated by E2F (Parise et at., 2006), this may explain the increased levels 
in cervical cancer cells. The reason for the C33A, HPV negative cervical cancer cell line, 
displaying lower levels of LAP2 expression could thus be due to the absence of the E7 
oncoprotein; however it has been shown that the Rb protein is mutated in this cell line 
and thus should perhaps show a similar effect (SchefTner et at., 1991). Rb is similarly 
often mutated in oesophageal cancer (Huang et at., 1993) and may explain the 
overexpression observed in the oesophageal cancer cell lines. In the SVWI38 cell line, 
the simian virus large T antigen has been shown to bind and inactivate Rb (DeCaprio et 
at., 1988) and thus explains the increased LAP2 expression observed in this cell line. 
While our study is a fIrst to identify and confIrm increased LAP2 expression in cervical 
cancer patient material, a similar preliminary genome-wide expression profIling study 
identifIed LAP2 as one of the genes in a cervical cancer proliferation gene cluster the 
expression of which is positively correlated with that of E6 and E7 mRNA (Rosty et at., 
2005). LAP2u mRNA overexpression has also been reported in several primary tumours 
and its expression has been shown to be correlated with tumour proliferation rate (Parise 
et at., 2006); however expression has not been determined in cervical or oesophageal 
cancer cells and overexpression has not been confIrmed at a protein level. Our 
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observation that LAP2P expression is elevated in cancer cell lines is in agreement with 
studies showing increased levels in neuroblastomas (Weber et ai., 1999) and various 
haematological malignancies (Somech et ai., 2007). 
While this study presents evidence of increased LAP2 expression in cancer cells, the use 
of LAP2 as a biomarker is preliminary. In order for the potential of LAP2 to be 
determined as a cancer biomarker, a larger patient cohort would be required to assess the 
clinical relevance of the up-regulation of LAP2. There is often considerable heterogeneity 
between patient samples and thus a more comprehensive study would need to be 
conducted to evaluate its suitability. Further laboratory-based studies are required to 
determine its suitability as a biomarker before the phases of assay development, 
screening and clinical trials can be considered. This would include the determination of 
whether its levels could be easily quantified. LAP2, previously known as thymopoietin, 
has been assayed from blood plasma at concentrations of <0.25 nglml and thus should be 
able to be assayed fairly easily (Twomey et ai., 1977). 
The observation that LAP2 is overexpressed in cancer patient material compared to 
normal tissue, as well as in transformed and cancer cells in culture, suggests that this 
protein may play an important role in cancer cells. Further investigation into the 
functional significance of this up-regulation was thus performed. 
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Chapter 4: Effect of LAP2 illhibition on cancer cell biology 
4.1 Introduction 
In order to detennine the biological relevance of increased LAP2 expression in cancer 
cells, two principle approaches can be followed. Either, the protein of interest can be 
overexpressed in a cell line which has low endogenous expression of the gene, via the 
introduction of cDNA plasmids encoding the gene of interest; alternatively, the 
expression of the gene can be inhibited in cell lines which highly express the gene. This 
can be achieved by transiently inhibiting expression using molecules such as short 
interfering RNA (siRNA), or short, stably transfected hairpin (shRNA) molecules. 
Because LAP2 was shown to be overexpressed in cancer cells, this study used transiently 
transfected siRNA targeted to the LAP2 gene to inhibit its expression. This technique 
takes advantage of the fact that short (21·22 nucleotide) duplexes, when transfected into 
mammalian cells in culture, can mediate gene silencing (Elbashir et aI., 2001). Briefly, 
transfection with siRNA induces the RNA·induced silencing complex (RISe), which via 
its endonucleolytic activity, results in the targeting, cleavage and degradation of target 
mRNA, which ultimately leads to gene silencing evident at the protein level (Aigner, 
2006). This process is illustrated in Diagram 4.1. 
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m lRI'S Dl 4. 1: Mrtha niilll of R.'IIA Inltrft rtnN in mamml lil n ,!'51tml . Long 
double-stranded DNA molecules et11~ the cell and ~ ciea\'a1 by Ihe c:IlZ)'lIIe DiCe!" 
11,1 fonn shoner siRNA molo:cuk •. Ahcrnall\~ly. siRNA mohx:ules.,.o tJc, introdocw 
dlrmly intO ~dl$ \\ hen: tlll'Y bt-comc 11'IC<l1"Jl'O .. ,ed ;nll,l the RISC C<lOlpl"lI. This 
association rcsulLS in the dl!8vage of 1o" RNA sense 51nmd by argonaute 2 (AG02). 
The "';'''.00 RISC-liRNA complc:x Wg~IS OOInpkmenlaty mRNA. Il'SUlllng in 
SlIeTW;ing of the c~pn:ssinn orloc gt-n~ ofinlcn:s1. 1'he RISC' I,RNA eompl~lI. can be 
fl:'Cyclcd and tbe process repealed on OIlier identical mRNA molecules (\\.'hIl~"'~1I(1 tl 
al .• 2(09), 
Nonnal 100 cancer c" lIs can be in one of four phases of lhe: cdl <:)\'Ie II any point In lime 
(",,~,~"\n-d in Co ll in~ ... 1 al •• 1997). ~ !U"C !he (1 , (gap I) phillie, In which the cell 
pr~,ntrcs IQ rt'flIiCalc ill D'<A, the S (DNA syn thesis) phast-. in which DNA rqlhC&lIon 
t8kes pll1Cc, the G1 (gap 2) pMSt', whl:f"C protC1l1! an: synlhcsiscd, or the M (mitosis) 
phase, when cell di \.'ision Ottllri . Quiescent, or non-dw,dmg ce lls. 8 .. , said 10 reside in 
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the Go phase and I:an rl:-CI1tn tIN.: celJ l:yeJc wh<.'fl conditions become fa,'oul1'lblc. 
Progression through lhe variOI,lS phases of t.he cell c)'dc is ughtly reguloted by cell cycle 
r<:gulatory protems (rev'cwed in Mum),. 20(4). Thcsc incll.lde cycl iTIS which bind 10. and 
IICtivate cyelin dependent kinal'CS (CDIes). ~uhing in cell cycle progression vi. a 
taseade of phosphorylDllon modtfiCDtions. Con,crscly if DNA damage is dCll'CICd. or Ihe 
cell ;5 undn s~s conditions (ei- serum dcrri"ation), eyelin dcpcndcn! I.:J lUtse inrubilon 
(CDK!s). also known as tumOur suppn:ssors an: induct.-d. and rulKtion 10 hah I:cll cydc 
progression. If the damage is I'IOt repaired_ or the streSs ath~"ialed, the: <:ell will undCTgO 
proi\nlrnmro cell dealh nr 8p<lpIO$is. 
ImpotUlrIt I:tll cydc r~ulatory protems include !he cyelins such as eyehn 01 . COK4. 
p16, p21 and p53 [n:v,ewoo III (Sherr t'I 01 .. 1999) .nd (Mumy_ ~)]. Cyelin OJ is 
expressed in respo1Uot: 10 milo!;enic Shmuli and its I:<pn:ssion is I'ICICc:s5IUY for the 
IIldllClion ofsuh!tqucnl eyebns ,,'lIh,n 11M: cell cyek CDK4 iJlhe kinase responsible ror 
pho~phol')latini and mllChvlhng Rb "hat oomplued 10 eyelln 01. pl6 m1u'b,LS the 
COK4-(:yehnDI compkll reqUIred for Rb phosphorylation and «:h:asc of I:dls inlo S-
pha5C. p27 and 1'2 1 a(:I 10 rq'ln:sll cychnE..{'DK2 II(:I,vil)'. These CDKI "'" mdw.;cd in 
response to contact ,nhibJuon. Tq'!llColi,c senescence and TGF~ Mgnl lllllg. In addition, 
p21 is IJO'SJlJnly I'C¥Ulalcti by p53 "hlCh 's &C1l"6ted in respo1Uot: 10 Dl\A damage. 
In this cbapl~r. !he effects of inhibilina LAP~ eJlp=sion, via the intmdl>Ction of LAP2 
5p.-.;:,fle siRNA molecules. will be detemUllcd Oil cancel cell biology. cell cycle 
regulalOry proleins and .. ell c~1c progress,on. 
" 
4.2 Result s 
4.2.1 LA!'! inhibition in cancer and transformed c('lIlines using siRNA 
molecules 
LAP2 pr(lIcin c};prcssioo was si!coccd hy transiently t1'1l/lsfect ing LA 1'2 ~iRNA 1Jl(I!«"!cs 
into cancer cells grov.n in culture, in order to detCTTlline the effects on the biology of 
cancer cells. The CaSld Illlo.l Hcla cervical cancer cell lines "" cre chosen ItS model ~ell 
lines for f .. nhcr ...... pcrimenls as they both displuy high levds of e~ lm:ssion (If LAI'2. und 
are routi!lC'ly used in our 1300mtory as edl lines representBtive of cervical cancer. LAP2 
protein Cl<prC$s100 "'a~ inhihited using a pool of three, lafgct-Sf)ecific. 20-25 nucleodde, 
cOllunercially available si RNA molecules (Santll Cru~ Bioux:hn(>logy). The LAP2 siRNA 
"as CJlpe<:ted to inhihit the expression of the alpha and bt:ta isoforms liS an alpha-specific 
siRNA is not D,·ailahl ... at present A rendom, non-targeting 20-25 nucleotide. control 
siRNA sequcncc WItS used as II control for n(>n'spccilic el1a:1S on gcne expression. as 
well as to «Jntrol for any changes induced hy the transfcclion rcagent. 
WeSlcm blot analysis conlirm~-d that then: "as a significant reduction in LAP2 
c.\pressioo (LAI'2u and LAI'2jJ). following LAI'2 siRNA tl1lnsfechon in CaSld celt$. 
which was sustained over !he number of "")"I assayed ( I'ig. 4.I.A). Tnmsfection with 
control siRNA had no cffect on LAf>2 protein Icvcls and LAP2 expression was 
comparahle to lel'cls obsCI'ved in untJ1U\Sfectoo cdl lysatcs. A similar decrease in LAP2 
C};pression was observed in HcLa cclt lySlltcs folto"'illll LA 1'2 siRNA trnnsreclion 
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j.' ;gUIT 4. 1; Inhib1lion of LAJ>2 u p relsiOD in cen'kal canCt'r rtll li nH. 
(A.) Western bIOI analJllH$ showing LAJ>2 e_~pression III umrealed (una) CaSk; ce lls aM 
cells It'8IISfe<:led wilb 20 oM control (C1r1) or LA I'2 siRNA up unli l live days pusl 
lranste.::liol1. (8 .) Wesl<:m blot an:llysi~ showing LAf'2 expression following LAI'l 
siRNA lransfOClion in HeLa cdls. ~.lUbu lin WIIS inclooed as 8 c{)mrol for protem loading. 
Rcsult~ arC representative of expcrimcnlS performed a1 Ic:u; • • wo indcpcndcnl limcs. 
(Fig. 4.1.8 ). The apparent ino::r~ In LAP2 e;o;pfCSSlon in the ~oIl1'ol. ~ornpar~-d to 
UDlr.U1:Sfecled Ild ... lysllles .... ·as due 10 dinCrmccs in protem looding. as p-tubuhn levels 
... crt' liso Incre~ m th(, control cells. 
Wrslma bIoIIIUd)"si~ thu~ reo,·ealed Ihat LAP2 siRNA ltaMienltransfectioM resu lted ill • 
sub5lanlial decrease In LAP1 protcon levds. IIlllnng the s.RNA suitable (or dd-ammong 
the< role of LAP! m the blologyofcln«rcells. 
4.2.2 [fr('c l ~ or LA!'2 inh ihilion on catu'U cdl hiolo~ 
-4 .2.l . t UT"l'("h of LA t'! llIlo ibl l ioll on n l,«r Ind lrln~ rorlll rd crll s Rro,, " IIndrr 
adhf l·rnt ~rll proli frra .lon fo nd itlons 
Having C$.abli5hod tN.t Inonsfeclion witll LAP2 siRNA sigruficantly reduccs the 
c.~p~:.slOn of LAP2. f",nctional clT«ts of this InhibItIon We!e dClemlmiXI. "The 
f"'mlam~l1 tal phellOtype assoc'ated WIth cancer cells IS the abiJi.y to prolifcrD'e rapidly 
nod ",ncomrollnbly. and thus W~ wlimed to delcnnme whelller LAPl plays a role in 
prol if~lion of cancer cell ~ wh~1l grown ulld.,.. .dherCnI growth corxltl;nru; in media 
cOll1ai ni ll glOO", serum 
CaSk; cell s wefC IrBosfec1l:d with 20 nM LAP1 or control siR.,'1A Bod cell proHfenllion 
moni loroo by I h~ M·IT a~~)" (Fig. <I .2.A). This colOluimetnc assay mcas~ cdl 
ml'tab()lic activi ty 3.~ lin indication of ce ll number. Our resul1s sho .... ed no sill'lificul11 
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Figu" 4.2 : Eff~t of LAP2 inhihltion (In cen"ieal U MeH cell flfolirent]oD. 
!A.) CaSk; l:erviclI! cancer .,ells ""ere either untrcmro (Unix). or Imnsfccloo Wilh 20 oM 
of LAI'2 (I! coruml (Clrl) siRIIIA and eel! pmlifernlion m(milon:<! up urm! seven days poS! 
Inmsfeclioo. using the MTI cell proliferation assay. (R.) The effect of lJI.P2 inhibmon on 
HcLa cell prolif<:l'IIlion Wa$ performed a.. described in (A.), E~perimelllS " 'ere pffionnwl 
in triplicate and Kopeatcd at least three independcnL limes. Results shown n:pres.:nl the 
mcan ± SD. 
difference in adherent cell prolifcrntion in LAP2 siRNA transfectcd CaSIti cell$ 
compared to ufllransfectoo and control siRNA transfectoo cells (Fig. 4.2.A). Similar 
results "'ere obtained in [lela cells sho"'ing LAP2 inhibilion in Ihis cdlline also did nol 
resull in an al!c!1llion in cell proliferation (Fig. 4.2.B). ThIs assay was repeated a number 
of limes 8l difTerem cell densities (datil nol shown), wilil. Ihc results consistently 
suggesting that LAP2 does not playa role in cervical cancer cell proliferation under 
adherent grQwth conditions. 
Because LAP2 also showed elevated e~pression in a transformed fibroblast cell line. 
SVW13S, lhe effecl of LAP2 inhibition on SVW138 ce ll s, wu also in\"l:Stigated. SVW\38 
cells wcrt: treated wilh control and LA 1'2 siRNA 115 described for lhe cervical cancer cell 
lines. Two lime points {three: and six days POSI transfectionl werc selected for the 8S!jay. 
Western blot anal)'sis showed II redoction in LAP2 protein Ie\"els 11 both 1hJ"e<, and six 
days post transfcction with LAP2 siRNA (Fig. 4.3.A). M1T usays for SVWI38 cell 
proliferation. when LA P2 e"pres:;ion was Inhibited. revealed Ihallhcre was no diffen:nce 
in proliferation bC1wccn untnmsfected. control and LAP2 siRNA lnutllfe<:ted cells (Fig. 
4.3.B). 
Together lhC!;e data sUHgt:St Ihal LAP2 does nOi appear to playa role in the cdl 
proliferation of cenical cancer cell lines and transformed fibroblasts wben grQwn under 
adherent growlh coooitiolls. 
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Flgur .. -I .J: Effe.:-. of LAI'2 inhibition on SVWIJ8 Ir.nsforn~d fibr/,lbla" «;11 
prolirerll,;on. 
(A.) WeSlcm biOI analysis showing LAn expression in SVWIJ8 filJroblasl cells "hieh 
were ,ransfected with 20 oM control (cui ) or LAP2 siRNA and protein hB,Yes,ed II zero. 
tbr~'e and six days POSL Ltansfcclion. (8 .) SVW138 cell proliferation wItS determinoxlthn:e 
and six days po5I Iransfeclion using Ihe MTT cell proliferation Dssay and v:uues 
expres>;et! rl'lali>'e to Day O. El<perimmts were performed In tripl icate ftl least two 
indqJeoocnllimes arul rcsulls shown rcpresenl 'he mean ± SD. 
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·40 2.2.2 t:fffels of L,\I'2 jnhihilion on fell prolirfr~ll on under ' arinll s fondili ons IIf 
MITS5 
TIu: benefits of trealing cancer wilh combination Iherllpics to synergistically enhance Ihe 
8C;tivit ics of individual trcaum:nlS are b.."C(lming inCl1'asi llgly "videnl. As an c,;amplc. Ihe 
usc of radiation lhtrapy togcther wi lh cbcmotilcrapcutic agents has been sllOW" to 
improvc IIl.Irvival associated with cervical cancer (Moore. 2003). While inhibitinll LAP2 
alOlIC did 1\01 appear to have a significatll e lTe..::t on the proliferation of cervical cancer 
celis. we IlCxt illvcsligall-d whether inhibiTion of LAP2 may enha,ICC the growth 
Inhibitory "ITc"C1 obscrVL-d when cancer f,;clls arc placed undcT sTressful condiTions; 
includ ing ( I) serum SlrC"liS-. (2) suess induced by f,;hcmothcl1Ip<.·\uic a!,'CnIS aud (3) stress 
induced by ancoorage.indcJlCndC1lt cood;,;oll!;. 
ti ) LAI'2 inhibilion a nd se rum strClis 
Olle of the rt:cogniscd phenotypes of Cllllcer cdls is that they POSSC"liS II self-sufficiency in 
growth signals (Hanahan Bnd W"';nbcrg. 2000) Bnd can thus prolifcl1lt~ \H ltl er low s<:rum 
conditions. This is however. II SIn:SS On Ihe cells and they prolifcrnte suhslllniially slow;,:, 
than cells \Oro"' " in vowth factor supplemcnted medium. We wall tcd to d/:lel1Tlin" 
whether inh ib iting the ,",xprcs£ ioll of LAP2 would 1Io\'c an eff~"(:t on ceil proli fcr3tioll 
under serum stress. 
CaSki cells were grown in 2. 4 or 10% foctal ca lf serum containing medium. and cel l 
prollfcm!ioll monito,ed over five days. Cd~ groW II ill 10% serum proliferated the fastest. 
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as ~l<P«Ied. tilllulleU by cetls IIfOwn in 4% serwn. No proliferation lI'as obSt.1'VeU for 
cells wown in 2% Iot'Nm. Under all three (onditiorlS lhere was no d,fferellCe in Ihe rale of 
proIiferallon bel"'«t1 Ihe unlraruifecu:t!. wmrol and LAP2 siRNA transfcclw celli. (Fij. 
4.4.A), CaSki cells "'~ also Ilel'Um starved for 24 Ilours prior to plBlin!! in 10"'. SCNm 10 
dcumni~ whether Uus ahemau~'e Conn of serum suess. and synchroniuuon of cell s 
w"hm tOO 0. phase, .... ould 1uI"e an effect 00 ceU proliferatIon follO\\inj LAP2 
mhibltlon. The !'ales of ( cit proliferation bet .... een unlransfected and comrol and LAP2 
sIRNA Iransf«ted cells did DOl. differ under these rondltl()DS. suggesllnj that LAP2 
mhibulon does no! enha~ the growth inhibuDI'y eITc..::t of snum dc:plehon. We IltXI 
detcrmined "htther inhib,"~ LAP2 c:x.prcss'l7D rould enhance the jro"th inhibitory 
effecl of otlter SII"C5!le!l including; response 10 CoctllOthcra!'<'uIK: dtugs and anchorage-
",dependent l!JOWlh ~'Onditions. 
(ii i C~II proiifH l t lu" In re~ jll.I" ~c w I. ,\PZ l!til th!! i"" a"d d ,clll"thuape utif d ru l!. 
IrQtmcnt 
ll~ clT.--ct of two apnplQSts·tnduclDII agems. S' tlllOl'Ollra(il (S'FU) IIlId ('i.l· 
dillfDill(dichloroplatinum (CP), in comblDatlon \\ ilh LAP2 inhlbillon. was used 10 
ooermino: II hewr LAP2 inhibition could mhance Ihe cdl death effect mduced by these 
d~", 
5TlI l~ ~ S·l'ha~·de!,ellllc!U, l'yrlm1<liM analogue. .... hich InhibIts thc thymKlylate 
synthCll5e l.'IIZyme .... hich is imporunl in DNA S)'fnhesis Hu.nl!C'llb.:h I!f ul , 1912) and 
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F1 i urr .&..t : EffK I of LAP2 lobibillon 00 \!roll rh factor i n d~l'r lld~ "1 rdl 
prcMi r~", llon. 
(A.) CaSIti cells " 'Cf'C either unl1'C:m:d (uniX). or "I:!'C lronsfech,d wiLh 20 0\1 of control 
(cut) or LAPl siRNA aoo pl~lcd in 2. " or 10". serum cOlluuning DMEM for the: lime 
tndicated. Cell prolifenllon lI'ti determrned by the additK,OII of Mrl" rcagem 31 cxh thlu: 
point. (8 .) CaSki cells .... en: lransrcckd as dc:scnbed abo'-c and IICOIm alan-cd for 24 
boors pnoc to plating In 10". 50InIm for the: durnliou of the MTT CI'U I'rohfefllllOll ~y_ 
Expcnmc\lIs \!o'er!: pcrformal In 1nplic<~lc aL IcaSI I" O mdcpcndem limes. R~uhJ $11011' 11 
rep<esem tho: mean ~ SO. 
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(llol,Iglnon cr ul., 1979)] and is a chemotherapo:l,ll1c agenl cummonly usn! in the tn:alment 
of cer."ical cnn<;:('t (Moore, 2003). cr. also widely used In th.c trepunnn of tet'\'iI;all:anccr 
(T811~'f$all, 200 1). is known 10 bind DNA and form add"",·u, which .ffo:cts 1M 
l:onforrn8t;on of DNA· associated proteins. thereby preventing I~ rqJair of damal;C(l 
DNA (Zamble C/ Ill., 1996). 
CaSki cells "'ere transfo:cu:d with control or LAP2 siRNA lind incubated for 48 hours 
pnor 10 ue::llment with 5' FU or CP fOT 96 houri. A ~ooccntnlhon of 1 I'M S'FU und 86 
n\l cr WllS found to inlubit CIISkJ cd l growlh by Dpproxlmludy 40-50% (Fig. 4.S.A and 
B). Our resulls shoI\' thai mhibllm¥ LAP2 expression docs IlOl al ler the ull d~al l\ e(l'el;1 
ofbolh S'FU and CP alUM (Fi" 4.5.A and B). 
(iii) CI"II I'r"l)lir ...... ' ;on in rtsl'OllSI" III 1. ,\1'2 inhihitl .. " 11I1drr (ondi l ioll ~ of 
wndlOra~('-jndellelld .. "t •· .. lIl1ro .. th 
Th~ ab rlrt~ of cancer ccll5 to prolifrnlle in tM absm<:e of D substrate (i.e in an 
anchorage-independent manner) IS D phellOtype obscn,.ed in ClUlCCf edls IUJd IS an 
mdication of tumourigenici ty (Shm f/ /II., 1975). II IS nonetheless a S1ress condItion ." 
tbsuc eultute systems. and the tell s prolifcrntc far slower than lhey would under II(!h(,rent 
Wowth conditions. To !VOw cells under anchorage·independent condItions. ",dIs Dt'\" 
plrned on poly-HEMA-(:oat~..t dishes. ..... hieh [lrcvelliS cell adh~"'S'(ln 10 the cui ture \ C>.,cI~ , 
A. 
B. 
JJ 
~i ,. 
" Ii 06 
c 
" 
" 
" 5' .·' ............. <11 
.... '<01 ,IlL" " 
~I'l .IRI'~A 
,~ 
~! : 1 ~~ , . ~ 
,! 
•• . -, 
~ 
~ 
Cioptotl_ 
<.'" .... 10/111'1''' 
LAPl,IIII"" 
~ I I 
• • 
• • 
, 
I I 
• • 
• 
Filtur~ 4.5: Err«1 or LAP2 inhihition on ch~l1)olhera~Ulic drul: senSili \'il y. 
(A.) CaSk] cells " 'erc transfCClcd with 20 nM of control or LAPl siRNA. Cells were 
treated ",im 1 11M y nuoroullIcil 48 hours lalcr and cel l proliferalioo mcasu .... 'ti by the 
addition of MIT rcagelll 96 hOUr>; post drug m,almem. (8.) CaSk; ce lls "'eTe u"!Insfcc.cd 
" ';Ih 20 nM of conlrol or LAPl siRNA. Cells were treated ",jln 86 nM Cisplalin 48 lKluts 
lalcr IIfId cell pTolif.;ralion mC8l!un:d by the addi lion of MTT rcagcm 96 hours post drug 
u'Calmcnt. Results shown represent the mean :to SO for experiments pt'TfonnL'tl in 
triphcate al leaStlWO indepeodent limes. 
" 
To detemline ,,'hettt.er LAP2 is required for cancer cdl prolifcnllion umJcr anchorage-
independenl I:fOwth <.:onditiuns. cells werc rc-suspcnded in I'\'. methy1cel1u1osc and 
plaled un poly-HEMA-coaloo iJ6..well plales and both ceU prolW:nl1ion and cnlony 
funnalion dClcmlined. As anchorage-independent cell!; proliferate at a slower ralC Ihall 
aill>I:renl <.:",lIs. proliferalioll wd COIUlly furrn~tiQn was monilOll'd at ~ight days . To ensure 
Illal LAP] prolein expressinn was slill inhibited eight days post LAP2 siRNA 
transfcctinn. western binI analysis from control and LAP2 siRNA transf~'Ctcd cells was 
pcrfonned (Fig.. 4.6.A). Anehor;lge-indepellde11l cell prolifcral ion. as measured by !l. IIT 
assay. n:\'ealcd that inhihitinn nf LAP2 in both CaSk; and Hela cells resulted in II. 
signiflCUllt docrea<;e in cell prolifernlion cumpare-d In cnnnu] siRNA lransfecled cells 
(Fi~. 4.6.B and C). Althnugh significant. LAP2 inhibninn resulted in all approximatc 30-
50"/. inhibi tion in anchorage·independenl cell proliferatinn. possibly due to the fact that 
100% inhibitiun uf LAP2 with ~iRNA was not achieved in InInsic11l tra115feclion. 
111 addition 10 measuring anchorage·imkpendent proliferatinn by MIT assay. the colonies 
formox! by control and LAP2 siRNA treated cells were viewed by microscopy. CnloniL'S 
from control wd LAP2 siRNA transfOX:IL-d cells wt:11: slalfled with p _iodo. 
nilroletmzolium IUld phologruphox! under brightficld microscnpy (Fig. 4.1). The m;uhs 
show lhat c..,Jooio:s derivox! fT1)TT) conlrol siRNA Ir!lRSfected cells app"'8r Jarg<:r Ihall 
cnlonies derived from LAI'2 siRNA tr.IIlSfcClcd cells (Fig. 4.1. 1), The colonies from 
eonlrol cells also had a more defined. regular shape compared 10 the LAP2 knockdown 
colonk-s wruch were amOl'J1hous and less dcfined (Fig.. 4.1.2). soggesting thaI some of 
tl=e cells were stressed. resulting in Illc cell death observed. 
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Fl!:urt 4.6: Effect of LAP2 inhibition on Rnchorage-Indtpt'lldent celt prolifera tion. 
(A.) CaSt ; ce:l ls wen> tran;;fectcd with 20 nM oomrol or LAP2 sIRNA and protein 
haJ'\csloo e Ight days post transfeetion. LAP2 prolein levels wen: dClennincd by "CSi<:rn 
bioI analysis. (8.) CaSk; co:lIs were lran~fec'cd Wilh eillll:r 20 nM control Or LAP2 siRNA 
and re-suspcnd~-d in J % rtlC\bylcelJulose prior 10 plahng on poly-liEMA-<oatcd 96-",,,11 
plal.:s. Cell proliferation was n~a.<urcd eight days IIOS\ u"lIsfe\:lion using MTT reagent. 
(C.) !lel.a cells wcrc sImilarly lreated aM rc~llhjng cell pmlifcmuon mt:nured. R"liul lS 
shown represent tt...: mean ± SD for ""perimen!!; performcrl in tnplicatc. and repealed at 
Icasl lhrcc independent limes (., p·'-aille < 0.05). 
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control si RNA LAPl siRNA 
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flg urr 4.7: Effec t or LAP2 inhibition on colon)" rorm Btion. 
CaSki cdl~ lIeTe ttllnSf""k-d with cit""r 20 nM control OT L..A1'1 s iRNA. ,uspended in 10•0 
methylcellulose and plnled on poly-~IEMA-wated 96-weU plates. Eight days POSI 
Inln.fe<:lion ~olon,cs Wetc $.nincd with 1 mglID' {J-,<><k>-nilroICl"",,,l iuID ror 16 hour. at 
J7°C aller which the colon ies Were photographed under bright11eld microscopy at 400x 
magnification on a MOlicam camera. Two ficids of view wen: taken lind an: denoted 1. 
and 2. Experiments were perfonned in triplicate and n'pealed 81 least IWO iodependent 
times. 
" 
~ _l _ ! _J Effffts o f L\ P! inhibition on c.-n C) d~ re~"hIlOr) prQtfl n t.' pr'-)11011 
Siner inhibiting toc aprcssion of W\P2 under anchorage-indeptlooe,tt growth conditions 
resulted in a g1'O" ... h mhibitory effeet. we next deu:rmmro the expressIOn of scleral cell 
c)'~1t ~g\ll "' orr proteins thai may lISSO<,: iatc with the obscr .. cd pb.:llOtype. Cell cycle 
progr-ession is regulated by the complex of C)'Clins wi th. either cydin d~IK',ldcnt kinasel 
((OKs). 0.- cyelin dc-pendrut w,asc InhibitOrs (COKls), "hleh acti ~ at c cell c)'tle 
progressiolL and initiate eeU cyele am:st m\p«II\'cly_ 
Protem was hal"' estro from control alld LAP2 SIRNA tllll1SfC'Cted cellt grown uoocr 
anchorage-Independent co."iLlions. md cell e)'tle protem e~pre$Slon dctcnmned by 
" 'cstem biOI analysis. LAP2 prOIein aplnSion was eonfilTllo:d 11,1 be decr\'ascd III W\1>2 
si RNA IflIlISfeclcd cells (Fig. "8). Western biOI analySIS for Ihe cell eyele prQtel llS; 
COK4. eyelin OJ. p16. p27. p2 1 .nd Rb was performed. Wholc COK4 and p27 kvch 
remained uochanged in IUpOnsr 11,1 LAP2 inhibitiolL pl!. alld Rb levds appeared 
partially inhibited. C)'tlm 01 1"1-.. 1$ dc:crcuc:.l and pl6 levels Increased $UbslantlBlly 
(fig. 4.8). The o~I""cd decrease 1M Rb lel'cb II fW'1hrr iml':Sligalro on Chapter S, As 
c)'tlin 01 lel cls we«: ~rrascd, and pI61e\-'eli IlI(:reased, Ihls suggested Ihlll Ihe ccll~ 
may show changes in the feil eycle. 
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Figurt' 4.8: EffeN of LAP2 inbibilion on growth regulatory prOldn upreuion. 
CaSk; cells we~ trnnsfeded with either 20 nM control or l.AP2 siRNA and Ie-plated on 
poly-HEMA-coaled disho."S 10 prewnt cell adhesion. Protein was ha rvested and subjected 
10 weSlem bioI ana lysis. LAP2, CDK4. p27, p21 . Rb. C)'din 01 and p l6 eXl"~s~ioll WII:; 
dclcnmncd using spL'Ci lic ontibodtl:s. ~-tubulill was indudoo to comml for protein 
loading. Resuhs shown are represenutive of experiments performed at least twO 
independenltimes. 
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4.2.2.4 Effl'tu of LAP2 inhlhition cn ~II e) d ~ pro)!r~5~itm undrr BFlClI orBl(c· 
lndt'pt'odt" lu growth conditions 
Illhihition of LA I'2 expression under anchorage-independent lP"owlh conditions st.owro 
thai Ilx:n: was DIl approximate thiny to fifty percent dCl;fcase in edl proliferatinn. and an 
aitcrnlion in expression of cd! eycle rcgulalOry genes tc~lin DI and p I6). suggesting a 
possihle alteration in the cell cycle profile of LAI'2 knockdown cells. Cell cycle analysis 
was thus pL-rfonned using nUorescenJ activated cell soning (FACS). I'ropidium iodide 
staming .. ·as used 10 measure the DNA conlent ofedls io order for DNA histograms. 
fl!prcscnIDlin: of Ihe cell c)'cle, 10 he genCl1,ltL-d (Krishan. 1975). The cell cycle profile 
\las analysed usin!', FlowJo and ModFit software according to the Dean·Jen·FOJ; modd 
[\I)ean '" uf •• 1974) and (Fox. 1980)], which filS a smooth cun'e 10 the S·phase. 
Background. edl aggregales and cell debris were galed OIIt for analysis, 
Control or CAI'2 siRNA IOlOsfccted CaSki cells grown", an anchoralle·ind~ndent 
mannL .... were analysed eight days post mlOsfcelion, Ihe time poinl al Which Ihe growth 
inluhilory clfcet was obser,'ed. Surprisingly. analysis of the cell cycle profile. whcn 
LAI'2 CJ(pn.:ssion was inhihited, revealed a simi lar cell distribution wilhin each phase of 
!he cell cycle compared 10 I;olllro is (Fi;;. 4.9.A). Quanlitati\'c analysis of Ihc cell cycle 
dam showed no signiftcJlm difTcreoce in 1M percenlage of cells within each phase of the 
ce ll c~le in comrol and LAI'2 siRNA InlnsfeClcd cd ls (Fig. 4.9.8 ). 
This dala SUIIIIC5!S thaI LAI'2 Knockdo""n cells cycle normally. indicatin!: thaI the 
decrease I!l cell pro liferation ObSelyed. ,..-as not liS a resu lT of ecll cycle aITeST. However. 
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.. ll:u rr ~.9: Effe,,1 of LAP2 Inhibition on I be "til .... ydt prof,le. 
IA.) The cdl cycle di~lribulion of CaSki ce ll5 lII"Qwn under andlOrage·independem 
"oodilions was delermined by now eyiomclry eight days following IransfC\: lion wilh 20 
",\1 conirol or LA"2 siRNA Cdls were 51ained with propidiwlI iodide /Uld Ihe cell cycle 
profile CJIHured using Cellquest software 00 a SO Bios.;ienceJI FacsCalibur and dala 
analysed wilh FlowJo and ModFit software. (B.) Quantilal ion of 11>1: percentage of cdl5 
within each phase orthecell cycle. (G,; gap phase I, S; DNA syntheSIS. G~: gap phase 2. 
M: mitosis) . Expenmcnts " 'en' pcrfonn~ in triplicate and repeated al least two 
independent limes. Resu lts repD.'"SCII1 the mean ± SO. 
" 
only cychng cells .... ere included ,n analyses. ~nd it IS possibl~ that lh~ d~-.:re~.e III 
prohfttllhon ob$c:"'cd. IDay have been Il$ a mull of cell d~alh • 
... . 2.2.5 [rrK'S or LAP2 Inhibition 011 cell dC.lh Ihrou!I;h .poploslf In ce ll s ~ ro" " 
undu .nehor.~f-lndejH":nd~n l growlh conditions 
In order 10 further in'UligaU: ,,·hetller the inhihilion of anchontgc·;mkpcndent 
prohfmuon ~·cd III LAP;!: knoo;kdo ..... n cells (oold be due 10 cell death mdw:cd hy 
aJ'OfltO>.I .... II qllanlllnll\ c apoplosis assay. measunol! this p3.nicular mode of programmed 
cdl death. "a. pttf"ormcd (ystcinyl amanate-speciHe prottlDJ!S, or CIUipa5CS. are • 
famdy of proICa5CS that are essential for mediating 1M BpoptOIiC phc:ootype throogh tOO 
t3fge1cd cleav.ge of~lf,.; IiUhslrtll~"i (rll"I'"''''cd .n N",holson Ind TIwmbcny, 1997). A 
cunl~rt:iaJly .,·.ilable ciI$p3sc activTt} a!iSlly \\,15 1hUli 1lsa110 1I.'.>oeM the :K:''''uy of tht: 
cllSpltie-) and _ 7 ~ymcs using. luminogcnic 1ctrapeptidc substrate eh.arn.: lcnSlK: of in 
";'"0 cleavllg<: sues. Lumino<;erlCc r<:Jeascd is proporIionaJ 10 SUbsb1l1c clca .... ge by the 
caspasc cnzymC!i and hence apo]lIotic ad;'·;ly. C.spasc acti.-j1y is knovo"tliO Ix an early 
and tran§ienl evenl in Ilpop1OOlS (rC\'i"""cd ,n Elmo.-e.. 2007) and thus caSp.:L><: """\"1Iy was 
ruca,urcd """cn <by.; poOl 1..Af'2 ~iRNA 1fIlI • •  ra: ';on, ~hgll!l)" carti~r .han "h~ .. ,he 
gro ..... th etree1 \\ ti ob!;c,,·oo. 
There .... as no ,i81\lr~am dLlTCfl'nte In caspase ....,li'o'1IY in control and LAP2 JiRJI.A 
Inlns(ee1ed C.Sk. ~ells ~rrl\'n LInder anchoragc-indcp:ndl:lll oondI 1 'on.~ ror ~'en days 
post InInsrc.:lion (Fig. 4. 1 O.A). Caspasc IK:tivily "''IS .150 fOWld 10 be i"qu'Vllll'fLt In 
" 
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flgu re 4.10: Efr~1 of LAP2 InhIbition on apoplO!liJ .. 
(A.) Caspas,,·317 aCII,,;ty relative to prolcin conccmral;on in conlrol and LAI'2 siRNA 
l20 nM) transfccK-d CaSki cdls GJOwn under ancbOl'llgc-indcpcndcm conditions for SC\'I'II 
dBys post u"amfcc\ion. (8 .) W~'SI"m bioI sh(lwing PARP clca\'8!1C in CaSki ceUs 
Iransf~"C1Cd wilb conlrol or lAP2 siRNA and platoo undlT an.:horagc·mdcp.. ... dcnt groMt-. 
conditions SCVCII days poS\ lransfeclion. Results show'" arc rcpres~·tllali\'c of 31 least two 
indt:'p<'ndenl ~l\""rimL"'15. Resu hs shown rep",S<.'I'l1 tOO rHl"an .:l: SO. 
c()I1wl and LAP2 knockdown cclls nght days post IJ"lmsfenioo (data DOl sOOv.-n). 111e 
lewis of poly (AOP-rib<ne) pol}~ (PARP). II Imo"'!1 caspase substnlte (NieholllOll 
1'1 ,,/ .. 1995), were also independauly determined C lea\'age oflhe 116 kD PARP prolelll 
;nto a 85 kD fragment lias beat shown 10 be an early c-enl in Bp<)pIosil (KlIUffman t'f ,,1_ 
1993). The clea\"l:d 85 kD fragment WIIS e>-iden\ in both cOl'I\n)l .nd LAP2 siRNA 
lransfcclro cells and 00 significant difference .... 5 obser.od (Fig. 4.10.8). Our mullS 
therefore i!8nnot conclusi\'ely link the effL'\!\ of LAP;! inhibluon on anchorage-
independent proliferalion 10 an illl:fC'~se in cell dealh via IIpOpI00IS. 
It i~ possible lhot the decreasc;n cell number in Ihe LAP2 siRNA lransfeclcd cells gmv.·n 
onder DllChorage-indo:pe!ldent ,ondit i<.>ns WBS due 10 an altc:manve mode of Cl'l1 death 
such as n«rOllis. NecroSIS typicBII y r\'.'liu lts in di m.pt;on of Ihe cell melllbl'lUle luding 10 
inilammHtiun, whl.~115 in the pl\X:eSli of apoptosi. lhe <.:ell I""""bnone rcmams mIllet and 
an mllammatory fC'spons.c ib I~ indU<..'od (revil.'"wed in Elmore, :W07). A more re<:e1l1ly 
di!ICovel"l'd m{)(\e of Prollfll1l1111cd Cl'1l death is aUUlphl!lY . .... herl' the cell degrndes cell 
c:ompootnlS withm Its own IYSOS01nes. and alternatively may hive been Ute process 
rC$polUlible for the cell death obKr ... ro. Due to limited timl' during the M.Sc. project, 
these pos5ibili1ic:s could not be invaiti\:oted prior 10 ilUbmiSliioa of this M.&:. IbeslS. 
" 
4.3 Disc ussion 
Having estabhfJlcd that LAP2 is overexpresscd in cancer samples, and has W: potential 
for usc as a cancer biomarker. the functional significance of this up-regulation in cancer 
cell. was invcstigDted. There are conflicting r~rts in !he litet1lture regarding the 
involvement of lhe LAP2 alpha isofonn in cell proliferation. Pekovic er (11. (2007) 
showed that inhibition ofLAP2o expression in human dip loid fibroblasts (HDFs) muhed 
in ~ docll:llSe in Ki67 siaining, a cell prolifer~tion marker. and induced de layed Gl M 
progression and evenlusl cell cycle arresl in the G, phase. This is in COnlrast 10 the work 
pcrt0nn~'d by Domer l'I <II. (2006), which showed lhal inllibiling the eApl"l:"SSinn of 
LA P2u in HeLa cel ls. resulted in an IOcrease in cell proli feration. and in fael favoured 
cel! cycle progression. These DU lhon; subSianlimed this rlnding by showing thai l...AP2u 
bioos to \he C·term;nus of Rh, Dnd that l.AI'2o expression affects transcription of E2~ 
larget genes. when: o\"erexpressed LAP2u is shown 10 repress E2F tsrget genc 
clIpression. Vlcek 1.'1 ul. (2002) also repon thai ovcrexpression of LAP20 results in the 
'"tub" inn or cell prolifcnmon IlOd G, IS cell cycle arTCSt Our study on bOIh LAP2 
,wfimns conlTfldicts thai of Domer 1.'1 01. (2006) Hod Vlcek er (11. (2002) llfld appears io be 
in liIX with thai of I'ekovic 1.'1 ul (2007) supporting a hypothesis IIiat LAP2 levels 
associale with cell proliferotion (albeit anchorage·illdcpernlcm). 
In our study. it ..... $$ only under anehomge-indcpendent growth conditions thm a growth 
P!lcnotyl'C change was observo:d "'hen LA P2 I:.'IpMlSlon was inhibi ted. This could be due 
10 the fact tllal dilfcrent signalltn@ pathw.),s an: lICl;valed under aDCooragc-independcnt 
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!V0wth cnndilions (Uttarrulng.h el ul" 20(3). Alterauoll.'i in gene expression hav" abo 
bcm Tepomd M1ween adherent an,l Tk1ll.adhcrendy growing cells (Kioos/tna 1'1 tI/., 
2(0)), 
'Mille we IuIv" nO! conclusively identified tile mechanism Ihrough ",tuch UP2 
InhibillOn results in cell death, our <!alii showingl,lp-rq:ulalion of the tumour suppm;sor. 
pl6 and dtcrtased cydln 01 expression. iUggClit th.1 Ihls may lLt'e been I ce ll cycle 
mhlbilory response lhal we lTllIy have mIssed. As an uynchronouily gt'O""lng popuialJon 
of celli Wll6 an.lysed, il may have been 1Th)n: appJOpllale 10 synchronise th" ~...,lIs prior 10 
ceIL cycle analysis, .Ii Ihe grD"'lh dtffertnCe t:\bSCI'\'ed rna) ha,,, bcm ton margonal k> 
reGisler in l1li .,ynchronow; population of cdls. 
Because only cycl ing cells .... ~ tndudcd for DIlAI}'5IS, we postulated 111..1 perhaps thet'e 
was an increase in cd] death In the UP;? knockdo,,'n ceUs. .. tueh "OIlid not be evident 
on Ih" cell cycle profile 15 die sub (i l ~ TqlrC!Senlali\'C~ or cell doublell and debri s.. 
11'15 ,,~chw:led. Two ,ndepmdml lpoptos.is assays, howe\-'er re'o'ealed no 5igI1lficani 
diff~oce tn apopiUS'S bo,.1"«'!l conuol and LAP;? siRNA lransfeclc:d ccUs. Tile decrnsc 
in ce ll numhCT in UP! inhibited celhi could possibly be lIS • r~'S\l 11 of necro~is 0<' 
llI1ophagy: !his forming Ih" basi, of fulUT(' ,,·ork. 
Wlule lhere are ~ponding Tl:lX'n$ on the furoclions o f LAP2~. Ihere j. conlnliliclOT) 
dala In Ih~ li lentlure arounoJ LAP2a'6 cxact role U1 Ihe cell as n .cem~ to perfi'rm 
conflicting functi.oM. Parise .. 1 al. (2006) idenlified an E2F inducibl e .nlisense lran...crtpl 
" 
CI<Pressoo from Ihe !irsl inlron of the L<\P2 gene. TIley sugg~~1 that givI'n lhal lAP2a 
plays a role in diverse. often eomradictory. cellular processes. it is likely thaI its 
expressioo is tightl}' regulated. and Illis could be due. in part. to !he 3lltist'tlsc truliSeript 
which C311 form doublc-strunded RNA kybrids, ro:sulting in the fomlDlioo of regulalory 
sIRNA molecules. TIlt' LAP20 isofonn is unique to mammals. and is IK)I evolutionarily 
cOIlsernd (Profe" (!I ul .. 20(4), Ilinling It the fact tbnt if its expression is in llibited. other 
I,rol~ins may cnmpensalc for loss of ilS tl<pression. \\!hi le tilt belD isoform is conserved 
OCTO$S scvcral species. a recent study has shown redundancy beN'eeD inner nuclear 
m~'rnbrane proteins such as lAI'211 and the Iamin B receptor (lBR) (AndcfflOn 1'1 al., 
2009). This may el<plain wily inllibition of lAP2 c~pn'SSion did IlOt :iCcm 10 ha"", 8 
dnnnatk effect on the cells. 
In summary. lhe curren! study in<iiCDle, that while LAP2 has the pOtemial 10 be a ..,am;:"r 
blolnarker. II may ha,e limIted usc as a therapeutic target as inhibition of Its expression 
only result"d in n marginal decrease in ancborage-independent cell proliferution. 
FUNn: work lhtu is of imert.st would be 10 OVCJexpress IAP2 in a nonna! cell Hue and 
dClemtine the eff~ls on the biology nf ',h" cell , as it is ",h:\'ated levtls thaI Btl' found iu 
cancer cells. and il is JlOssibly only when its eJtprl:SSiotl is increased, c~n effects be seen. 
The struCtura.! role of LAP2 in nuclear d)l11amics and IlOSt·mitolic nuclear assembly In 
eanecr cells is also of in lcrest It could be in Ihese processes th~t LAP2's ovcrexpres.<;ion 
in cancer bo:.::omes relevant. 
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Chapter 5: Effect of LAP2 inhibition 011 Rb expressio n le"els 
5.1 Introduction 
The rt:1lll(obla~H'nla ph,\cin (Rb) i. an Imponalll tulilour suppl1!>sor, .... hlch plays D 
critical role In rcgul at in~ cell t)'cle pro~n:ssion (n .. ,\·ie'''I:rd in Nevins, 2(01). It 
functions Dt the OilS transHion point " here, in its hypophosplKlrylaled stale. II hinds 
to. and inal:ttvlllCS the transcription fattor. ElF (Minnacht and Weinberg, 1991). 
When cdlg In the OJ phllSl: recehe j,lTO\\'lh promoting signals. cydin 0] binds to and 
act"'at",, CDK4, which in tum phosphorylates Rh. This causes the Induction of 
cychnE-CDKl complc.~cs and results in hypcrphosphorylation of Rb, tilTgctinS il for 
degradation: resulting In the release ofE2F. thereby shmulating the trnn!ll:ription o r s-
phase gen~ and proJ,:T<:S$ion 1010 S·phase (Diagram 5.1). InactivatJon or targeted 
degradation of Rb in canccT is thus often inl~'1P'al to the uncontrolled pro liferation 
charactcnstlc of cancer cells. In CCl'VICIlI tanccr, the HPV enoo<kd E7 onooprolcin 
lal};ets lhe Rb protein for ciegrndmion (Boyer I!I of .. 1996). while in oesophageal 
cancer Ihe Rb encoding gene is often mutated (HuulIg e/ al .. (993). In addlliooto the 
role of Rb in regulating cdl cycle progression, II hJ. al!>C ik."Cn ~ho\\ II 1<1 be ,mporlant 
In the procCS!WS of senescence (Shay t'l al., 199]] und ciltTerenhah<>n (TC"ev.ed in 
Ko!\: nJak O!{ al .• 2(05), 
" 
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01 1M ,~"r\ObIIISlDml. IR~) prO'~~ 
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Diagra m 5.1 : Th ...... ukaryotir crll eydt and th t rolt of Iht Rb IUlilOur iupprtUor 
prolein . The G, (gap 1). S (DNA synthesis). Gl (gap 2) and M (mitosis) plwes oflne 
cell cycle are r<:pres<lnlcd as a pie chul1 v .. ilh SClChOllS mdica1m .... relative lime spent 
within each phase. G, cells. upon stimulll1ion by milOgens, cause C)\'lm 01 10 bind I(), 
and activate COK4. wbicb phm;phorylatc:s Rb. This causal cyelin E to bmd COKl 
and bypel'phosphorylale Rb. resulting in lhe release of E2F and allOWing pn>grc:$S1QIl 
inlO S·phose. The eye1inA-COKl compl..,,; funa ions within Ibe S·ph~ and the eyel in 
B·COKI complex within milusill (Ko lch l'Illl.. 2002). 
Rb has also been shown 10 inlerac:t "'ith A·type lamills III well as the LAP2 alpha 
isofonn. and il has b«:n $Uggested that 11 is through these mtC'fllf,;tiOllS that Rb is 
tahcn:d in the nucleus enabling il lo perform its regulatory functions HJohnsoo el al. 
2()().:1) and (Marklewio;;z ('t al .. 20(2)). Howe\n. lhe oacl nature of !he immtction 
between LAP2 alpha and Rb. and !he rulK1ional ~Ievancc thc:Rof is nOi clear. The 
mtCl'llClion bet'nUl Rb and LAna occurs ",i!mn tbe unique ('·terminal tail of Inc 
alpha ,sofOlTll IMark,ewia; rl al .. 2002). and there 15 Ihus no t''ldcnce in the I11CT81urc 
Ha\'ing observed a decrc:~ in Rb aprasion when LAP2 is inhibited. the ilim oflh,s 
chapen was \0 ,",·cstiplc this obscn·ation limber. Our results IDdil:ate thlt while 
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mlllbl!1OIl of LAP! hIlS no dfec! ()Il Rb mR \lA It> el ..... it doc:s r<.':!lult In D morc rap,,1 
dcgnodatlOn of the' Rb protcin 
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5.2 Results 
5.2.1 Errrrl's or LAP2 inhibilion on Ilh prolrin r .\prrssion 
A$ Rb 1$ a prmein a~socI3,ed ""l lh grow.k regulat()l), mechwlIsms (Nevins. 200 1), we 
had previously (Chapter 4) monitored Its e:<pression in response 10 LAP2 inhibition. 
' nten:stillyly, our results indical~,(' that In hibilion of LAP2 C,II.~lOn r~ulted in an 
associated decrease in Rb le\cl~. 11lis observat ion Wl\.i therefore funhcr explored by 
lrunsienl.y transfcctiny CaSk, cells wl lh conlrol or LAP2 SIRNA and Rb upression 
determined when LAP2 was inhibited Intntunocytoeilc1nistry was pcrfonned on 
pamformaldehyde·fuoo LAP2 , iRNA transfccled cells. "he", J.AI'20 expressIOn was 
visibh: in lhe Cy3 fluorescenl cltanncland Rb II1lhe AJ~a488 channel (FIg. S.I.A) 
Our results soowed Ihat in cells in ""hich LAP2 had effc:clilely 00cn inhibited. a 
corresponding decrease in the levels of Rb Wlb obsened. As this was a transien t 
LA P2 siRNA experiment, 001 all ~lIs in the panel showed ~P2 inhibi tion. Thus 
shown in thIS panel are cdls where LAPl was DOt inh ibil<!d, and II IS notable tila. 
these cells ha,e OOITcspondingly h'!;her Ie, cis ofRb. Quanufication orlbe floorcsccnt 
Images te'alcd a sigmficanl dc:ac:asc III Rb Ie, cis wben LAP2 w:.s inhibited (Fig. 
5,1.8). 
This finding "'as mdependently confirmed by western blot analysis. where a 
.nuccoursc following traR$fecllon ",Ib LAf'2 SIRNA ~howed a CQlTC$pollding 
redl>t'lioo in Rb CJl prcsSlOn (Fig. S.2.A), 
92 
A. 
•• 
I :: 
• • 
• 0 . 
::i ~I i.L_ 
.... ... lIt."~ 
0 ,\1'1 
" 
• f 
• j 
UPltlRN ... 
figure 5.1: Effec:1 of LAP2 Inhibit/O il 011 Rb prQlein e~prcnion . 
(A.) Immunofluorescence showing LAP2u and Rh expression in control l1Ild LAP2 
siRNA lfllllsfccled cel ls parafonnaldehyde_fixed four da.ys ~I lnUl~feclion. A Cy3-
conjugated goal ani I-rabbit ~ondary an. ibody WItS " sed (0 detect the LA I' 20 specific 
primary antibody and an AlexB488-WDJugHwd gOal "nli· mouse sccondRry antibody 
was used 10 delect Rh. DAPI staming indical.::! cell nuclei. A 20 Ab negative control 
(secondary antibody only control) WIlS included to show specificity o f the 
nuorescenlly lagged S«QI1dary an11bod ics. Im8gl"S wen- caplun:d on a Zeiss 
tluore5Cl'llCe micT0500pc al 400" magmficalion using AXlovlsion 4 .6 software. (D.) 
QuwlIilalion of LAP2u aoo Rb ~xpressioll ill at leftst 100 t AP2 s iRNA transfeelcd 
celJs was performed using AxioVision 4 .6I1Ofl ... ·1II"C. R~sults sho .... n rqm:scnl the mean 
ot SD ror cllpcnmmts repeated I t lca~1 two indepel1dL'TI1 ti ltll$. i', p'VaJ Il C < 0.05) 
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Figu r r S.l: EIlK l or LA 1' 2 inhib ltloll Oil Rb prOlrin t l pr tnlon. 
(A.) Rb c:JIipresslOO folluwingl..AP2 siRNA Iransrection. Pmtdn was ham':Sled:1I two, 
Ihrl"C, four lI:ud Ihe daY' polIl Ir.m5rection and 1III1Ilysc:d by WCS!lTll hlQI analysis for 
Rb c:JIi~ion p·t\lbulin was lIlcluded lIS II CQrIlrol for protelll loadinl. (8 .) Rb and 
pOOspoo.Rb le\"els in LAPl knockdown tells. I'roI:l'ln was hanesloo nom cc:lls fin: 
daY' post C(lnlrol or LAP2 sIRNA transfl"dlon lind Rb Icn,h; dCh:rmined by ""CSlern 
"Ivl Hnllipili. A I'h""phv·Rb Illltibody ""'-"a:nism¥ Iii<'; 807 and 811 ptlosphurylauxl 
saine rfl!i.lduC5 Willi uso:! lIS an indication of phos~Rb 11:\ds. p.lubulin was 
mcluded as D protein loading oontrol. Resul ts shown are n:pn:sl-ntallvc; of C'XpcriDletllll 
performed at least Iwo mdqx:oocnt timcs. 
Rb can eIther be In II phosphoryl'lOO or unphospllOr)'I:llcd stale. In order 10 deltmllnol 
whether l.AP2 Inh,blllon al1lT$ tbe phosphorylatIon status of Rb, an antibody 
W'jIClJng the 807 IUld 811 serine resid ues (RbS807/811), ..... hich are knoWll Rb 
phosphorylation sitts. WlIS used in .... estern biOI analysis. CaSki ceUs were transf«1l'tl 
"uh oontrol or l.AP2 siRNA, ~tein tJltnlcted. and Rb arK! phospho-Rb le\·d, 
delennlned. Concomitant WIth th .. dcaeasc: In wl.31 Rb Icvds. " '15 • dccR'asc In 
phospho (SS071811) Rb (Fig. !i.2.B). 
S,Z.Z Eff« ls of LAP2 inhibition on Rb mRNA expression 
J laving obset"\'cd Ihlll Rb protein levels were reduced wh~" l.AP2 tJlprnsion was: 
1Il1llbited, we inVC5tisatoo ..... bether LAI'2 inillblllon rcsultl'Cl In II lranscriptiolllli 
change in Rb e"pression. In order 10 ascertain IIIIS, Rb mRNA levels were detennintd 
in LAP2 knockdown ~lls. RNA was: cxtrocled from oonlml Bnd LAP2 si RNA 
transfectcd cells and RNA inleerily confirmed on II fonnalddlydc-agarosc gel, where 
112:1 rotio of 2SS to [SS rRNA and an ,b:senCl' of smearing ind,caled good quality 
RNA (Fig. !i.l.A). R.NA was subsequently n:v .. '"I"SC transcribed inlo eDNA and 
cxprnsion of LAP2u .nd Rb detennmed rdaun: 10 the cyclophilin housekeeping 
'lj:r gene by Ihl: 2 method (Liullo: and Schmingen. 20(0) by Real-ume RT-PCR 
analysis. Transfccl ion \Oinh LAPl siRNA resulted in a significant decrease: in LAP2u 
mRNA levels (Fig. 5.3.BI, "hile nO difference in Rb mRNA exprc:sSlOO was obsened 
under these conditions {Fig. S.3.C\. Tht'S(" ll'Sulls indica!C" tha, LAP2 does nO! rc:gulll'lc 
Rb al a tr.u"l5Cripllonal lc:vc:l, as Ihcre was no change 10 mRNA e~prcssion. and 
s ulUtesl II poOSI-trunsc:ripllonal regulation ofRb expression in LAP2 mhibited celtl. 
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Figurt' 5.3: Effecl of LAP2 inhibit ion 011 Rb mRNA t'xprfuloll. 
(A.) RNA ",-as C)\1I1'(,100 from control and LAI'2 sIRNA Ir.msfccled C&Ski C\'ll s in 
lriplicale fOllr days JlO5t IllIl1.'I fection and RNA In tegrity delmninro on ;I 1.5"'. 
fonnaJdchydt'-agarose gd. 28S and 18S are repmimtativc ofnbosomal subunits. (R.) 
cON A was synthesized from RNA Ob1311l00 from control ~nd LAI'2 sIRNA 
Irans f~"(:ted cells and I..AP2u mRNA t'X)X'eSSion was quanti!al;""I) dc:ICIl111ned relalL\'f 
to Ihe cytiophilin house· keepIng gene by Real.lime RT. f'CR anaJ )'!iis using Ihe r~~ 
m~'\hod. (C.) Quantl lal ion of Rb mRNA Qpression rclallve 10 cydophil in as 
described in (B.). Experiments ""'ere performed in triplicate and n:f'C~led HI least two 
mdcp . .. n dcnt t ime~. Results shown are Ihe meM :t SO (0. ~\'alue < a ,OS). 
5.2.3 [ffeets of I .A 1'2 inhibitio n on Rb pro tein st3hilit ~ 
Th~ is evidence in tht li tl!l'1lture to suggest that Lamm A affects the pmtcin stability 
or Rb (Johnson el 01., 20(4). and since LAI' 2u is knoYon to interact principally \O.ilh 
Urnin A (Dedlat 1'1 ul .. 200(11) and Rb {Marklcwicz I'f ul., 2002}, we neJ(t detennined 
wherher LAr2 plays a role in rt'llulaling Rb protein stabilily which could explain why 
protem, lJ\d nol mRNA lellcls. were reduced when LAP:! Wl\5 inhibited. In orda 10 
test thi$ theory, cells wert IllII1!lreCled with either control Qr LAP2 siRNA for 48 hours 
and ITCated with 50 J.lg/ml cyclohcJ(illlido tCHX) to inhibit ncw pmt:ein 5)"IItbCllI S. 
Protem Wl\5 harvested at various lime points rollowing LAP:! Inhibition and CHX 
trUlmenl and Rb and I\-tubulin protelO levels dclennmed by western blot analysis 
(Fig. SA-A). After treatment with CHX for Ihe indicated limes. I decrease in Rb 
expression in both oonUl)1 and LAP2 inhibited cells wu ob$cr.·ed (Fig. 5.4.A\. TIus 
dCl.Teast appeared 10 be to, greater utent in Ihe LAP2 knockdown cells compared to 
the oontrol <:.:111. Rb expression was '1uan1italed n:lati \Ie to [l-Iubul in by densitometric 
anal ysi s or Ihe ..... e>stem biOI band inlens.t)' and Ih .. \"n lu~ ellpreooed ",hui'·e w Ille 
values al Day 0, 10 ensure thllt proteID 5labililY_ and 1101 expression. was bemg 
measured . Log \'&lues wert pinned on 'IiCIlnet" plot and a linear Irendlinc filled to !he 
data points (Fig. 5.4.0). The miults mow thai Rb was Icss st3ble in LAP2 siRNA 
transfooed cells. lIS the gradient or the LAP2 SIRNA graph IS steeper than Ihat of the 
control SIRNA graph. and cxlTapOlaunn to • point v. here there iJ no Rb expression, 
would occur at an earlier time pomt. As log \·:dues were ploued, the followmg 
equation WIIS used 10 quanht:lli vely de1ennine the half-life (II' ) of the Rb protem 
under tkesc: COntlttions: I I ':I' log2Im v. here nI - ()"-<Vx on , line3f iJ1lph. The hal f-life 
o fRb in controlt ransfected IX:lIs YoU calculated 10 be - 13 houl"ll Yohile the half·life in 
LAP2 SI RNA lransfected celts was - 1 hours. mdlcating mal Rb was less Slable, and 
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Figure 5.4: Effett (If LAP:! Inhlbidoll Oil Rb prolelu Jlahlllly. (A.) CaSk, cells 
"ere trans rcn~'d Wllh 20 nM controlOf' LAP2 SIRNA IlIId mcubalcd for 48 hours prior 
10 treatmCOI WIth 50 .,glml crclohcximide (CIIX ). Protein \\as lull'\'csu:d at 0, 1. 6, 12 
and 24 hour Inlcr ... al5 folloll ing CHX treatment and Rb Ic~el s dt1ennined by WC$lcrn 
bIoI UnOI)'5LS. (8.) Quanll1allon of Rb ~prb.s ion o:lIl1l\'C 10 B-Iubultn. !knsl1ometn\: 
analysis of " CSII.'m biOI band Intensity "as perfomlcd using GcncTools softwIU"C and 
the h;lI(. hfe of Rb cakulaled based on the gracltent5 of the Iwo graphs. Rcsuhs shown 
are rcprescnlalJ~C of at I~sl 1""0 mdcpcndcnt expenmcnls. 
" 
more rapidly degraded . wben LAP2 "'35 inbibited. This data ~ugg""l!l that LA P21'ta% 
11 potential role in Rb protein stability and degradation. 
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5.3 Disc ussio n 
o...r observation that LAP2 illhibilion results in drnc~sw Rb 1 ... ·\'~ls IS in agrC~TI1ent 
"ilh th31 made by Peko,jc 1'/ al. (2007). Th.;se authors also analyso.-..l phospho-Rb 
(RbS780) cxpression "III."fI LAP20 was inhihi tcd. and found an e-.en greater uCt."fcast: 
In expn::ssion o f this phospho-form. ThiS papl.."f &190 shows Ibll1 LAP20 CXpre$liIOll 
afT~"C\li the localisation of tiny I"t'Inpinlng Rb, wh .. "TC inhibition of LAP2a CIIpn;sslOn 
e3u.d Ihe phospho-form. RbS79S, levels 10 remain unchanged. bUI rather its 
di, lrtbl,ltion is re- Iocalised from the nuclCllf oompar1nK"fIt 10 nuclear $pI.<Cldcs. We 
similarly sho"oo a decrease 111 Rb and phospho-Rb (RbS807181 1) Ie-.·cls In LAP2 
inhiblu:d cervical canCel'" cells. To dale. no funhl."!" studies on the mcchalllsm behind 
!.h IS obsl.-rved decrease In Rb ..,,;pn:ss1On whc:n LAP2 IS inhibited ha"e been reponed 
To dl..1t;.'Iltli ne whelher LAP2 was ;n"oI\OO in rq:ulating Rb ~I a t~plion311""el. 
R",al ' lIml' RT-f'CR analYSIS was pcrfonned 10 dcu:mllne Rb mRNA levels in LAP2 
knockdcll',"fI cel.ls Our rcsullS I"C\caled Ihal Rb mRNA lranscnpt levels WI,."!"C nOI 
alt~"fCd. suggeslmg LAP2 rq;ulatd Rb C)(pn.'$$IOO 31 a JlO$I·lrnnscriplional 1L-\'cl. It has 
bt.-en sho""fI Ihm LAP2cz btnds Lamm A (D..dlBl .. I al .. 2000a) and that tog~1her they 
can fonn a complex with Rb (Marki(Wi~ .. , al., 2002). Work by Johnson 1'1 al. (2004) 
sho--.ed thaI mhibtung Urnin A expression resulted in a dc<:rcasc in Rb levels. They 
found thai th is decn:asc III expression was lIS Q !\,'SU1t of protcll.wmal dCllfadation o f 
Rb. and thai LlIllIin A plays a ral.; in mediatmt: Rb stability_ This associaiion was 
found 10 be functiona ll y rell:\'wlI as Ihe stahi lisillion of Rb hy A-type lrunins WIIS 
shown 10 be n~ry for p l6-indl,lccd ccll cyclc lUl\."St (Nina ~llIl __ 20(6). 
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The. ..... ork on Lamin A's invoh,(.'It1l'nt in Rb sl3bility indicalcd thnt this pr01cnsomc_ 
dependent dcgradaliOfl of Rb occurs indepcnd<..'tIlIy of Gankyrin and MDM2. which 
are known mediators of Rb degradat ion (Ninll el al .. 2007) . • Iow<.."\'er. inlcreslingly 
LA I'2u has bc.en SOO,,'tI to associllle with lhe B and C [KK);els of Rb (Markiewicz 1'1 
III .• 2(02), and as these authors noted. th is is the same site to whidl MDM2 binds 
(Xino l'I Ill. , 1995). TogelllCr. thL-,;c results sugg~"St thaI LAP2u is importanl for 
tcthering Rb in Ihe nucleus. and perhaps when LAI'2u is inhibitcJ. Ihe MDM2 site is 
available for MDM2 to bind. lind Rb is targeted for degr:ldahOn resulti ng in a 
decrease in Rb protcin le\"els. The involvcment of MOM2 in Rb stabil ity. when 
LAP2u is inhibil~-d . could in fUlure experiments. be delermin~-d by o"crcxpressin~ 
p14, n CDK inhibItor known to inhibit MDM2 function. 
In ~ummnry. there SL'QIIS to be an associmion bL1wccn LAP2 and Rb expression. It is 
proposed thaI LAP2 plays a role in stabilising tile Rb protein. thereby preventing its 
deJ;'ndatl<m; howe"e' furthc, ,Iud,c' w-e "''lUln;d to ~upport this themy Ulld to 
det(:nnine Ihe siglliflcunce of Ih .. in1 enlClion. 
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Chapter 6: Conclusion 
6.1 Expression of LAP2 in cancer 
Expression profiling to detennine differences in gene expression between normal and 
cancer patient samples with the aim of finding novel tumour markers, is an important 
area of cancer research. These tumour markers can be used as a diagnostic tool if the 
change in expression is shown to be an early event in cancer development, or if only 
found to be expressed later in cancer development, can be used to assist prognosis and 
patient management or predict responses to cancer therapy (Kulasingam and Diamandis, 
2008). 
Earlier work in our laboratory has shown that there are a range of genes differentially 
expressed in cervical cancer tissue compared to normal tissue using such expression 
profiling technology (van der Watt et ai., 2009 and unpublished data). One of the cDNAs 
shown to be highly expressed in the cancer samples was one encoding the LAP2a 
protein. This finding is in accordance with a similar expression profiling study performed 
by Rosty et ai. (2005). The LAP2 gene encodes alpha, beta and gamma protein isoforms 
which interact with nuclear lamins; thereby playing a role in nuclear architecture, as well 
as nuclear dynamics (Gruenbaum, 2000). 
The work in the present study validated the increase in LAP2a expression observed 
following analysis of the microarray data. Real-time RT-PCR analysis performed from 
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cervical biopsy tissue, confinned an increase in LAP2a mRNA expression in the cancer 
tissue compared to nonnal tissue. Similarly, an increase in LAP2a protein expression was 
observed following immunohistochemical staining of archival patient tissue sections. 
These fmdings were extrapolated to cell lines, where increased expression of both the 
LAP2 alpha and beta isofonns was observed in both cervical and oesophageal cancer cell 
lines, as well as transfonned fibroblasts, indicating an association between LAP2 and 
cellular transfonnation. 
This study is unique in validating the up-regulation of LAP2 expression in cervical 
cancer tissue. There have only been a few of reports correlating LAP2' s expression with 
cancer and this data is derived from large-scale genome-wide arrays [(Agrawal et al., 
2002), (LaTulippe et al., 2002), (Welcsh et al., 2002), (pomeroy et al., 2002) and 
(Yokota et al., 2004)]. Our study revealed an association between LAP2 and transfonned 
and cancer cells and suggests that LAP2 may be a useful tumour marker. These findings 
are, however preliminary and a larger sample size will have to be used in order to predict 
clinical relevance. 
6.2 LAP2 inhibition and cancer cell biology 
While there have been a few genome-wide analyses identifying the LAP2 gene to be 
associated with transfonned cells, to our knowledge no functional studies have clearly 
described LAP2's role in cancer. There is, in fact, controversy surrounding the role that 
LAP2 plays in nonnal cells. There are some indications that overexpression of the LAP2 
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apoptosis in LAP2 siRNA transfected cells, as shown by caspase and P ARP assays, and it 
is thus likely that the cell death observed was as a result of necrosis or autophagy. 
6.3 LAP2 inhibition and decreased Rb expression 
Interestingly, we found that LAP2 inhibition resulted in a decrease in Rb expression. This 
is in agreement with a study by Pekovic et al. (2007) that suggested that there may be an 
association between LAP2a and Rb. Work presented in this project showed a decrease in 
Rb protein expression in cells in which LAP2 was inhibited. It was also shown that LAP2 
played a role in maintaining the stability of the Rb protein, as mRNA levels were 
unaffected in LAP2 knockdown cells; whereas treatment with a protein synthesis 
inhibitor, reduced the half-life of Rb in LAP2 knockdown cells. It is likely that the LAP2 
alpha isoform was responsible for exerting these effects, as it has been shown to interact 
with Rb (Markiewicz et al., 2002). 
Inhibition of LAP2a's interaction partner, Lamin A, has also been shown to negatively 
affect Rb stability (Johnson et al., 2004), and together these data suggest that this LAP2a-
LaminA complex is at least partly responsible for protecting Rb from degradation. This 
decrease in Rb expression did not seem to have an effect on cell proliferation which 
would have been expected, as if Rb is targeted for degradation, E2F would be free to 
activate transcription of S-phase genes. The role of LAP2a in maintaining Rb stability, 
and the effects of this interaction on the cell cycle and in the cancer state, clearly requires 
further investigation. 
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The precise role of LAP2 in cancer cells is still debatable. The apparently contradictory 
data in the literature and found in our study suggests that LAP2' s role in both normal and 
cancer cells, is a complex, and probably multifaceted one. 
6.4 Concluding statement 
In summary, this study has validated the up-regulation of LAP2a in cervical cancer tissue 
compared to normal tissue as previously suggested by expression profile analysis. This 
up-regulation was shown at both the mRNA and protein levels in biopsy samples, as well 
as in various cancer and transformed cell lines. The data indicates an association between 
the expression of the LAP2 alpha and beta isoforms and cellular transformation, and 
suggests that LAP2 has potential for use as a cancer biomarker. The functional 
significance of this overexpression in cancer cells was not fully elucidated; however the 
study did suggest that there would be limited potential for the use of LAP2 as a 
therapeutic target, as inhibition of its expression only partially altered the proliferation 
rate of cancer cells used in this study. 
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Appendix B: Solutions 
B.1 Tissue cell culture 
lOX PBS (500ml) 
40 gNaCI 
1 gKCI 
5.75 g Na2HP04.7H20 
19 KH2P04 
Up to 500 ml with dH20 
Heat Inactivated Foetal Calf Serum (FCS) 
Heat FCS at 56°C for 30 minutes 
Store at -20°C until use 
Complete DMEM medium 
450 ml Dulbecco's modified Eagle's mediwn (DMEM) 
50ml FCS 
5 ml Penicillin and streptomycin (PIS) 
Complete KSFM medium 
500 ml Keratinocyte Serwn-Free Medium (KSFM) 
5 ml PIS 
Bovine Pituitary Extract: 50 J.lglml for EPC2, HCX, HCX-E61E7 
Epidermal growth factor: 1 nglml for EPC2, 26 nglml for HCX and HCX-E61E7 
Trypsinisation solution 
0.5 g Trypsin 
8 gNaCI 
1.45 g Na2HP04.2H20 
0.2gKCI 
0.2 g KH2HP04 
10mMEDTA 
Make up to 1 litre with PBS 
Cell freezing medium (DMEM) 
5ml FCS 
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5 ml dimethyl sulphoxide (DMSO) 
40 ml complete DMEM medium 
Primary cell culture cell freezing medium 
9mlFCS 
1 mlDMSO 
Bank's balanced salt solution 
4.5 mM KCI 
0.3 mMNa2HP04 
0.4 mM KH2P04 
1.3 mMCaCh 
0.5mMMgCh 
0.6mMMgS04 
137mMNaCI 
5.6 mM D-glucose 
Boechst stain (0.5 f.1g/ml) 
5 mg Hoechst No. 33258 
100 ml Hank's Balanced Salt Solution 
Store at 4°C in foil 
Fixing solution 
1:3 glacial acetic acid-methanol 
Mounting fluid 
22.2 ml 0.1 M citric acid 
27.8 ml 0.2 M Na2HP04.2H20 
50 ml glycerol 
pH 5.5 
Store at 2-8°C 
D.2 Real-time RT -peR 
1 00 ~l DEPC in I litre dH20 
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lOX MOPS buffer (1 litre) 
41.86 g MOPS (0.2 M) 
16.6 ml3 M NaAcetate (0.005 M) 
20 ml 0.5 M EDTA (PH 8.0) (0.01 M) 
RNA loading buffer 
0.72 ml formamide 
0.16 mllOX MOPS buffer 
0.26 ml formaldehyde (37%) 
0.18 mldH20 
0.1 ml 80% glycerol 
0.08 ml bromophenol blue (0.025%) 
Store at -80°C 
1.50/0 formaldehyde-agarose gel (100 ml) 
1.5 g agarose 
10 ml lOX MOPS buffer 
89ml dH20 
5.4 ml37% glycerol 
5 JlI (10 mglml) ethidium bromide 
2% agarose gel (100 ml) 
2 g agarose 
10 ml lOX Tris borate EDT A (TBE) 
90mldH20 
5 JlI (10 mglml) ethidium bromide 
B.3 Western blot 
RIPA buffer 
3 ml NaCI (150 mM) 
1 ml Triton X-I 00 (1%) 
1 g Na deoxycholate 
1 mllO% SDS (1 %) 
1 mIl M Tris pH 7.4 (10 mM Tris) 
IX protease inhibitor (200 mM Phenylmethylsulfonyl fluoride (PMSF), 100 mM EDTA, 
1 mglmlleupeptin, aprotinin and pepstatin) (added just before use) 
IX phosphatase inhibitor (1 mM Na3 V04) (added just before use) 
Store at 4°C 
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30% acrylamide solution 
30 g acrylamide 
0.8 g bisacrylamide 
0.1 g SDS 
Make up to 100 m1 with dH20 
Store at 4°C covered in foil 
8% denaturing polyacrylamide separating gel (lOml) 
3.39 m1 dH20 
3.75 m11 M Tris pH 8.8 
100 J1l1O% SDS 
2.7 m1 30% acrylamide 
150 III 10% Ammonium persulphate (APS) 
15 J1l N,N,N·tetramethyl·ethylene mamine (TEMED) 
4% denaturing polyacrylamide stacking gel (Sml) 
3.65 ml dH20 
0.625 m11 M Tris pH 6.8 
0.650 m1 30% acrylamide 
50 III 10% SDS 
60 III 10% APS 
6 J.ll TEMED 
2X Laemmli buffer 
40m1l0% SDS 
2.5 m1 p·mercaptoethanol 
5 m1 glycerol 
1.25 m1l M Tris pH 7.0 
Few grains of bromophenol blue 
1.25 m1 dH20 
lOX running buffer (SOOml) 
20 g glycine 
31.6 g Tris 
50m110% SDS 
Make up to 500 m1 with dH20 
lOX tranfer buffer (SOOml) 
72 g glycine 
19 gTris 
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Make up to 500 ml with dH20 
IX transfer buffer (I litre) 
100 ml lOX transfer buffer 
200 ml methanol 
700 ml dH20 
TBST (I litre) 
50 mll M Tris pH 7.5 (50 mM) 
30 ml NaCI (150 mM) 
500 J11 Tween20 (0.05%) 
920mldH20 
Rapid Coomassie stain 
10 ml acetic acid 
0.006 g Coomassie brilliant blue 
90mldH20 
Destain solution (200ml) 
10 ml methanol 
14 ml acetic acid 
176 ml dH20 
B.4 Immunofluorescence 
4% paraformaldehyde 
Prepare 16% parafonnaldehyde (PFA) 
16 g PFA to 80 ml dH20 
Cover with foil and stir for 1 hour not letting temperature exceed 60°C 
Add few drops 10 M NaOH until solution becomes clear 
Filter through 0.45 J1M filter 
Adjust to pH 7.0 with concentrated HCI 
Store in 2.5 ml aliquots at ~20°C 
Add 7.5 mllX PBS to make 4% PFA 
50 mM NRaCI 
0.265 gN~CI 
100 mllX PBS 
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0.2% gelatin 
100 mg gelatin in 10 ml I X PBS 
Sudan Black 
0.03 g in 10 ml 70% ethanol 
DAPI (4',6-diamidino--2-pbenylindole dibydrocbloride) (O.S mglml) 
10 mg DAPI in 20 mllX PBS 
MowioI4-88 
2 g Mowiol 4-88 
2 ml glycerol 
4mldH20 
Leave at room temperature overnight 
8 ml 0.2 M Tris pH 8.5 
Incubate at 50°C for Ihour with occasional stirring 
Store in 2 ml aliquots at -20°C 
Add 2.5 % anti-fading agent (N-propyl gallate) day before use 
Centrifuge at 1200 g for 5 minutes to remove insoluble particles before mounting 
B.S Cell proliferation assays 
MTT Reagent (3-(4,S-dimetbyltbiazol-2-yJ]-2,S-dipbenyltetrazolium bromide) 
5 mglml in PBS 
Weigh out 100 mg MTT in sterile 50 ml conical tube 
Add 20 ml sterile 1 X PBS 
Vortex the mixture and incubate at 37°C for 15 minutes 
Filter sterilize the solution through a 0.2 J.lM filter 
Store in the dark at 4°C 
Use within 1 month 
Solubilisation Reagent 
10% Sodium Lauryl Sulphate (SLS) in 0.01 M HCI filter sterilized 
Dissolve 25 g of SLS in 250 ml dH20 
Add 76.6 J.ll concentrated HCI 
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B.6 Colony forming assay 
1 % methylcellulose 
Weigh 1 g of methylcelluose in 100 ml glass bottle 
Autoclave powder 
Warm 100 ml complete DMEM medium and add to powder 
Shake until clumps dissolve 
Shake overnight at 4°C 
12mglml poly-(HEMA) 
Weigh 2.4 g poly (2-hydroxyethyl-methacrylate) 
Dissolve in 20 ml96% ethanol by rotating at 65°C until melted (-1-2 hours) 
Dilute 1: lOin 96% ethanol i.e. 20 ml in 200 ml 
B.7 Cell cycle 
RNase (SO Jlg/ml) 
300 III 1 mg/ml RNase 
5.7ml1XPBS 
0.1 M PIPES pH 6.8 
3.02 g PIPES in 100 ml dH20 
pH to 6.8 to become clear 
Propidium Iodide Solution 
0.1 M Triton X-I 00 
0.002 M MgCh 
0.1 MNaCl 
0.01 M PIPES pH 6.8 
0.01 M Propidium Iodide 
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